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The Nonlinear Mixed Effect Viral Dynamic Model can easily handle unbalanced repeated 
and continuous measures data for individuals and is also popular in many other research 
areas such as biology and pharmacokinetics. Wu et al. (2004) [13] described a Nonlinear 
Mixed Effects Biphasic Model to estimate short-term population and individual viral 
decay rates in their study. Perelson et al. (1999) [43] and Ding et al. (1999) [15] reported 
that initial viral decay estimated for viral decay models would be good markers of the 
potency of antiretroviral regimens. The aim of this study was to model viral decay rates, 
and check the validity of the model for the set of data provided and investigate whether the 
relationships found with baseline covariates and long-term response are consistent with 
Wu et al.’s (2004) findings [13]. 
 
The Nonlinear Mixed Effect Single and Biphasic Viral Dynamic Models were fitted, and 
their respective initial viral decay rates were derived. In this study, analyses and reports 
are focused on the first-phase viral decay rates of the models. The study found that the 
actual treatment groups were more potent than the control group. It was found that actual 
treatment effect and the number of multi-PI mutations at baseline had impacts on the 
initial viral decay rates for both models. Besides, baseline HIV-1 RNA levels had an 
impact on the initial viral decay rates for the biphasic model. There were no significant 
differences in the initial viral decay rates for different ages, ethnicities, and gender groups. 
 
The study also shows that the initial viral decay rates were somewhat negatively correlated 
with the baseline HIV-1 RNA levels. A strong correlation between the initial viral decay 
rates and week 1 virus load reduction from baseline was observed. It was also observed 




suppressed virus load at week 24. Also, individuals with higher week 1 virus load 
reduction, i.e. early viral dynamics, were more likely to have suppressed virus load at 
week 24. These findings suggest that the antiviral potency or the initial viral decay rates 
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SECTION 1:   INTRODUCTION 
1.1 Study Background  
In HIV clinical trials, one important measure of the effectiveness of an antiviral treatment 
is the extent to which it suppresses the viral load in the patient’s plasma. Once therapy has 
been initiated, achieving and maintaining an undetectable HIV viral load is an important 
treatment goal. Most current tri-therapy regimens achieve reasonably good viral 
suppression over the short-term.  An outstanding challenge is to find regimens that sustain 
viral load suppression over the long-term, which is made difficult by the mutating aspects 
of the virus [30]. 
 
The viral load will drop within a few weeks and remain low long-term when patients are 
taking an efficacious therapy and their virus is sensitive to this therapy.  The development 
of resistance from the virus to the drugs (through mutations) means that the viral load 
might eventually rebound [30]. 
 
The data is often summarized by calculating the change from baseline in viral load at each 
visit and also, by categorizing subjects as responders or non-responders at an acceptable 
long-term time-point (e.g. 48 weeks) according to a Time to Loss of Virological Response 
(TLOVR). From this, subjects will be classified as non-responders if they discontinue 
their treatment, or their viral load never falls below a certain threshold (either 400 or 50 
copies/mL), or their viral load rebounds above the threshold [30]. 
 
Wu et al. (2004) [13] described a nonlinear mixed effects biphasic model to estimate 




relationship between the individual early viral decay rates and subjects’ characteristics, 
and also investigate whether the early viral decay rate could predict the subjects’ long-
term responses [30]. Perelson et al. (1999) [43] and Ding et al. (1999) reported that initial 
viral decay estimated for viral decay models would be good markers of the potency of 
antiretroviral regimens. 
 
In Wu et al.’s (2004) study [13], viral dynamics in HIV-1–infected individuals aged 12–22 
years were similar to those of HIV-1–infected adults over 22 years and infants. Also, the 
3TC/ZDV/EFV regimen may be more potent than 3TC/ZDV/NFV or other regimens. In 
addition, early viral dynamics or week 1 virus load reduction measurements may be useful 
in evaluating the potency of antiretroviral regimens. The first-phase viral decay rates were 
positively correlated with baseline RNA levels and week 1 virus load reductions [13]. 
 
1.2 Initial Issues  
Assumptions with regards to independence, constant variance and normality are crucial for 
modeling to obtain valid results. Most standard statistical techniques such as the unpaired 
t-test, linear regression and the chi-square test for association, assume that each of the 
primary observations are independent of all of the others [1-3].  
 
If repeated observations are taken within subjects [1-7], the independence assumption can 
be unsuitable because observations within an individual tend to be correlated with one 
another. If we take two observations at random from the same individual, they are likely to 
be more similar or correlated in value than two random observations from two different 




repeated observation in an individual may provide less additional information than a new 
observation in a new individual [1] and can be affect inferences.  
 
In this case, assuming the correlation structure is crucial rather than assuming that the 
errors are independent of one another incorrectly. If the independence is not to be satisfied, 
the estimates from the result will not be reasonable. In specific, the test statistic and test of 
significance will be incorrect which can impact in a model selection process or any 
inferences.  
 
There are alternative modeling approaches or estimation procedures which offer the 
possibility of analysing non-independent error structure such as Mixed Models, 
Generalized Estimating Equations (GEEs). Also, Generalized Additive Models (GAMs) or 
many other regression methods are when it is used in a Mixed Models or GEE estimation. 
Of the aforementioned, GEEs approach is only going to work for a linear problem, (i.e. 
linear in its parameters); however, an appropriate linearizing transformation is not always 
possible.  
 
The Nonlinear mixed effect model is an alternative methodology that deals with this 
problem. Observations are assumed to be independent across all the individuals in the 
model, but it allows for the existence of within-subject covariance thanks to repeated data 







The main objective of this research is to model viral decay rates and check the validity of 
the model for the set of data provided and investigate if the relationships found with 
baseline covariates and long-term response are consistent with Wu et al.’s (2004) findings 
[13]. This will be done as per what is outlined below: 
 
       1.  Deriving initial viral decay rates for each subject. 
       2.  Identifying baseline characteristics which are correlated with the viral decay rates.              
       3.  Examining whether the initial viral decay rates predict long-term response. 
       4.  Examining whether the relationship of the initial viral decay rates with baseline 
             covariates and long-term response are consistent with Wu et al.’s (2004) findings.               
       5.  Examining other methods that could be used for analysis. 













SECTION 2:   LTERATURE REVIEW 
2.1 Nonlinear Models 
How do we determine whether we should fit our model to our data using linear or 
nonlinear regression? If the relationship between the response variable, y, and the 
explanatory variable, x, appears to be roughly linear then linear regression may be a fairly 
reasonable thing to do. However, even if the plotted relationship appears to be distinctly 
nonlinear, this does not necessarily mean that a linear regression model cannot be used 
[12]. 
 
Even if the plotted relationship does not appear to be linear, with a careful choice of the 
form of the model, we may wish to fit to the data if it is still possible to use ordinary linear 
least squares regression, also, it is much easier than using nonlinear least squares which 
use an iterative search method in general. If we can express the relationship between the 
response variable ,Y  the explanatory variables ix  and the parameters in the form 
 += XY  (linear in their parameters), we can fit the model to the data using a least 
ordinary squares fitting approach. Sometimes it may be necessary to perform simple 
transformations on the variables to allow the model to be expressed in a linear form [12].  
 
Nevertheless, this is not always the most appropriate solution because once we transform 
the variables, important assumptions about the errors associated with the data which are 
normally distributed may no longer hold1 and the inference on confidence and prediction 
intervals should be treated cautiously [12]. 
 
 




Then, we can use a Generalized Linear Model (GLM) as an alternative method. Models 
that are based on a particular subset of nonlinear relationships can be fitted using the GLM 
framework. The subset of models that are allowed are those that have a linearizing 
transformation. Within this GLM framework, any class of non-normal error distributions2 
can be expressed as a member of the exponential family can be specified [12].   
 
However, if the model does not possess an appropriate linearizing transformation, and also 
if we are fairly confident that the error distribution consists of normal errors with zero 
mean and constant variance, then nonlinear regression using nonlinear least squares is a 
viable alternative [12].  
 
In summary, we are interested in specifying an appropriate model for the relationship 
between the response variable and the explanatory variable. If a linear regression model 
using linear least squares cannot explain the relationships very well, i.e. if we can’t 
transform the form to be linear in its parameters, then, nonlinear regression using 
nonlinear least squares is one of the alternatives to fit the proper model which can 
explain/predict our data well.  
 
2.2 Nonlinear Mixed Effect Models 
Nonlinear mixed effects models, also referred to as hierarchical nonlinear models3, are 
considered as a popular form for analysis for the repeated and continuous measures data 
on each of the individuals when interest focuses on individual-specific characteristics [18]. 
 
2 GLM is an extension of standard linear models and we can relax the linearity, non-normality and even 
constant variance assumptions. 
 






Mixed effects models have some advantages for example, they can easily handle 
unbalanced repeated measures data that occur in many areas such as pharmacokinetics, 
economics, biology, and many others, and the flexible variance-covariance structures of 
the response vector which allows for the nonconstant correlation among observations [17]. 
It is intuitively appealing because the notion that individuals’ responses all follow a 
similar functional form with parameters that vary among individuals seems to be 
appropriate in many situations [16]. 
 
Nonlinear mixed effects models are mixed effects models in which the intrasubject model 
relating to the response variable to covariate (time typically) is nonlinear in the parameters 
[17] and may involve both fixed effects and random effects. Model building for nonlinear 
mixed effects models is considered as the process of determining the characteristics of 
both the fixed and the random effects so as to give an adequate but parsimonious model 
[19]. 
 
Several different nonlinear mixed effects models have been proposed by many scholars 
such as Sheiner and Beal (1980) [38], Mallet, Mentre, Steimer and Lokiek (1988) [39], 
author and author4 [17]. In this dissertation, a slightly modified form of the model 
proposed in Lindstrom and Bates (1990) [35] was considered. This model can be 
presented as a two-stage hierarchy model which in some ways generalizes both the linear 
mixed effects model of Laird and Ware (1982) [36] and the usual nonlinear model for 
independent data of Bates and Watts (1988) [37] [16]. In the first stage the i th observation 
on the j th individual is modelled as in the following formula: 
 
4 Lindstrom and Bates (1990) [35], Vonesh and Carter (1992) [46], Davidian and Gallant (1992) [34], 






                        ijijijij xfy  += ),( ,       ,,,1 Mi =          inj ,,1 =                           (1) 
 
where f is a nonlinear function governing within-individual behaviour of an individual-
specific parameter vector ij and ijy is j th response on the i th individual. ijx is the 
predictor vector, ij  is a normally distributed noise term, M is the total number of 
individuals, and in is the number of observations on the i th individual [19].  
 
In the second stage, the individual-specific parameter vector ij is modelled as: 
 
                           ,iijijij bBA +=       ib ~ ),0(
2DN                                                    (2) 
 
where ijA and ijB are design matrices for the fixed and random effects respectively and 
 is a p - dimensional vector of fixed population parameters, ib is a q - dimensional 
random effects vector associated with the i th individual (not varying with j ). D2  is a 
(general) variance-covariance matrix. Also, it is further assumed that observations made 
on different subjects are independent and that the ij are iid ),0(
2DN   and independent of 
the ib  [16, 18]. 
 
Different methods can be used to estimate the parameters in model (1). In this study, 
maximum likelihood and restricted maximum likelihood estimation was considered. 
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In general, this integral does not have a closed-form expression when the model function 
f  is nonlinear in ib , thus different approximations have been proposed for estimating it. 
Some of these methods consist of taking a first-order Taylor expansion of the model 
function f around the expected value of the random effects in Sheiner et al. [32] and 
Vonesh et al. [33]. Others have proposed the use of Gaussian quadrature rules (in 
Davidian and Gallant (1992) [34]) [17].  
 
Nonlinear mixed effects models can be operated using the NLMIXED procedure in SAS. 
In this dissertation, the NLMIXED procedure will be applied to fit the specified nonlinear 
mixed model by maximizing an approximation to the likelihood integrated over random 
effects5 .  
 
The NLMIXED procedure assumes that we have an observed data vector iy  for each of i  
subjects, Mi ,,1= . The iy  are assumed to be independent across ,i  but it allows the 
existence of within-subject covariance since iy , each of the elements, are measured on the 
same subject. As a statistical mechanism for modeling this within-subject covariance, 
assume that there exist latent random-effect vectors of small dimensions which are also 




5 PROC NLMIXED only implements maximum likelihood, whereas PROC MIXED can perform both 




PROC NLMIXED fits nonlinear mixed models by maximizing an approximation to the 
likelihood integrated over the random effects. Different integral approximations are 
available such as the principal ones being adaptive Gaussian quadrature and a first-order 
Taylor series approximation. However, a variety of alternative optimization techniques are 
also available to carry out the maximization and the default is a dual quasi-Newton 
algorithm [11].  
 
We are able to use the estimated model to construct predictions of arbitrary functions by 
using the parameter estimates and the empirical Bayes estimates6 of the random effects in 
PROC NLMIXED [24]. 
 
 
2.3 Nonlinear Mixed Effect Multi-phase Viral Dynamic Models 
Wu and Ding (1999) [14] introduced an application of hierarchical nonlinear mixed effect 




6 Estimates of the individual parameters by modes (or mean) of their posterior distributions given the data, 





Figure 1:  Illustration of the different phases of plasma viral dynamics following antiviral 
drug treatment in Wu et al. (1999) [14].  In the phase of intracellular and pharmacological 
delay, the dotted line denotes non-steady-state case before treatment [14]. 
 
According to the illustration, if the data on the transition phase and rapid decay phase are 






is suggested. If the data on the rapid 
decay phase and slow decay phase are available, the model t
t
ePePPtV p 
 −− ++= 210)( is 
suggested. Also, if the data on the slow decay phase and leveling off phase are available, 
the suggested model is tePPtV −+= 20)( , where Parameter iP  represents the initial viral 
production rate, and parameter   is a possibly confounded clearance rate of long-lived 




They also have developed a nonlinear mixed effects biphasic viral decay model to 
estimate population and individual viral decay rates [14, 26] where the antiretroviral drugs 
are not assumed to be perfect [27]. Before that, Perelson et al. [25] developed a two-phase 
plasma viral decay model which assumes that there are two major HIV-infected cell 
compartments which are productively infected cells and long-lived infected cells. 
 
According to their model, the viral dynamic model after initiation of antiviral therapy, i.e. 
including treatment effects, can be written as [15]: 
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where IV  and NIV denote the concentration of infectious virions and non-infectious virions 
respectively, and 1T  and 2T denote the concentration of two infected cell compartments, 
productively infected cells and long-lived/latently infected cells, respectively [27]. 
Parameters 1  and 2  represent the protease inhibitor drug efficacy in the two infected cell 
compartments and 1 and 2 represent the protease inhibitor drug efficacy in the two 
corresponding compartments. Thus, the overall combination treatment potency in the two 
infected cell compartments can be defined by )1)(1(1 111  −−−=e and 





Wu and Ding (1999) [15] have also shown that the total virus observation, 
)()()( tVtVtV NII += , in this model can be approximated by: 
 
                                   tdtd ePePtV 21 21)(
−−
+= ,   ctt  ,                                                 (5) 
 
where ct is the time that the “shoulder” disappears (usually 2 or 3 days) [15]. Parameters, 
1P  and 2P , are reparametrized parameters from the solution of (4). Figure 2 shows the 
observed data and model-fitting result using model (5) for four selected patients from the 
above application [27]. 
 
 
Figure 2:  The Population nonlinear mixed effect model of model (5) fitted individual curves 





In addition, they showed that parameter 1d  and 2d  are the decay rates of the two phases of 
plasma virus and can be approximated by: 
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Rd                                                              (6) 
 
where ckTNR /)1( 1101 −= and ckTNR /)1( 2202 −=  are the baseline reproduction/ 
clearance ratios of the virus from the two infected cell compartments. Three factors, loss 
rates of infected cell ( 1 and 2 ), baseline reproduction/clearance ratios ( 1R and 2R ) and 
treatment effects ( 1e and 2e ), determine the decay rates. Hence we can use viral decay rates 
to compare the potencies of antiviral therapies if other factors ( 1R , 2R , 1 and 2 ) are 
homogeneous between treatment arms (ideally using a randomized design) [27]. 
         
Based on model (5), to estimate population and individual viral decay rates, Wu et al. 
(2004) [13] used a nonlinear mixed effect biphasic viral dynamic model as follows [13,14, 
27]:  
 
               ),()]exp()exp()exp()[exp(log)]([log 22111010 ttdPtdPtV iiiiii +−+−=                (7) 
 
where )(ti  is a HIV-1 RNA measurement error (on the 10log  scale) with mean zero, and  
)(tVi is HIV-1 RNA copies/mL plasma at treatment time t for the i th subject. The viral 
decay rates for the i th subject are ii bdd 111 +=  and ii bdd 222 += , where the fixed-effect 
parameters, i.e. 1d  and 2d , are the population decay rates for the two viral decay phases. 
ib1  and ib2  are random effect parameters assumed to be iid ),0(
2
1bN  and iid ),0(
2




respectively, that quantify the between-subject variation of viral decay rates. Parameters 
ii bPP 311 +=  and ii bPP 422 += are “macroparameters”, with )exp()exp( 21 ii PP + being baseline 
virus load at time 0=t  (the day of starting treatment) [13, 14, 20, 26, 27]. 
 
The fitted virus load trajectories from 6 selected subjects using the model (7) are shown in 
figure 3 in Wu et al. (2004) [13]. 
 
 
Figure 3:  HIV-1 RNA data (dots) from 6 selected individuals and corresponding fitted 





Wu et al. (2004) [13] only included HIV-1 RNA data from day 0 to week 4, i.e. with a 2-
week window, during treatment to fit the biphasic viral dynamic model. This decision was 
made for several reasons to eliminate the possibility of falling below the lower limit of 
detection, i.e. 400 copies/mL, or viral rebound may occur after 4 weeks in the data and 
also, the viral dynamic model is valid only for the early stage of treatment [13, 14, 28].  
 
They also excluded the rebounded data, an increase from the previous virus load 
measurement within 4 weeks for a patient [13]. If the HIV-1 RNA level fell below the 
limit of detection within 4 weeks, they only included the first limit of detection value to 
prevent an artificial effect. Their analysis and report focused on the first-phase viral decay 
rates; the second-phase viral decay rates for individual subjects may not be reliable 
because 60% of the total number of subjects did not have the data on the second-phase (no 
viral decay data after weeks 2) in the study [13].   
 
In another study by Wu et al. (2003) [20], to fit the biphasic viral dynamic model, the 
HIV-1 RNA data from 0 to week 8 on treatment was only included because weeks 8 was 
the time when subjects might change their treatment. They also excluded the rebounded 
data if there was a viral rebound within 8 weeks and if the HIV-1 RNA level fell below the 
limit of detection within 8 weeks; they only included the first limit of detection value.  
 
Anthony et al. [23] suggested a simple and flexible nonlinear mixed effects model for the 
trajectory of HIV-1 RNA until rebound. They were interested in the relationship between 
the lowest level of plasma HIV attained after initiation of therapy and the time until 
rebound [23]. In the study, they modelled the initial 2-week follow-up. The first-phase 





                       )();( 010 tttf iii −−=  ,               0=t (2 days
7) < t < 0t                    (9) 
 
where the parameter i1  is the rate of decline during this phase, and ),( 00 tf ii  = , the 
expected 10log  viral load for subject i  at time 0t  [23].  
 
After the initial phase, viral load is assumed for 0tt  to be the sum of two distinct 
components which is the one that declines in response to therapy, and the other of which 
may either decline or increase: 
 
                  )}(exp{)}(exp{(log);( 030210 ttBttAtf iiiii −−+−−=  ,       0t < t          (10) 
 
where iA  and iB are the levels of the two components of RNA at the start of the second 
phase (at 0tt = ); i2 0  and i3 are the rate of decay of first component and the rate of  
change either growth or decay of the second component respectively. The first exponential 
term in (10) implies that a component of the HIV-1 RNA continues to fall log-linearly. 
For some subjects (with i3 > 0), the second component may increase log-linearly, perhaps 
reflecting resistance; in others ( i3 < 0), it will continue to decline. This model guarantees 
a smooth transition from RNA decline to RNA increase. The two phases (9) and (10) are 
combined by imposing the constraint that the two mean equations agree for 0tt = : 
 
                                          iii BA 010 )(log =+                                                            (11) 
  
 
7 They do not include the day 0 values in the analysis and start instead with day 2 since no measurements are 




For subjects with viral rebound; i3 > 0 a turning point iT  can be defined, as the time from 
baseline to reaching the minimum expected viral load. This is given by: 
 
                  )}/()}/ln()/{ln(;max{ 323200 iiiiiii BAttT  +++=                               (12) 
 
For subjects whose HIV-1 RNA continues to decline throughout the second phase; i3 < 0, 
the turning point is not defined [23]. 
 
They fit the equations (10) and (11) jointly using a nonlinear mixed effect model, where 
the subject-specific parameters are treated as random effects. For the subject ,i  the 
response is )( ijiij tyy = , inj ,1= . The values )100(log2 10=ijy  are censored. And they 
assume independent normal errors: ijijiij tfy  += ),( ,  ij  are iid ),0(
2DN   [23]. Also, to 
impose the condition i2 0 , they reparameterize 
iei
 =2 . The condition (11) and the 
restrictions iA , iB > 0 are modelled by taking )1/(10
0 ii eAi

+= ,  )1/(10 0 iii eeBi

+= . 
And the random effects vectors = ),,,,( 310 iiiiii  are assumed independent 
multivariate normal with unspecified covariance matrix are i are iid ),0( GN , where G  is 
an arbitrary positive-definite matrix [23].  
 
Although this model is not intended to describe the long-term behaviour of HIV-1 RNA in 
response, it seems to appropriate for an analysis that only considers progression up to the 







SECTION 3:   METHODS  
 
3.1 Data Available for Analysis 
3.1.1 Data Description 
The HIV dataset was provided by GLAXOSMITHKLINE (GSK) Research and 
Development for the proposed project. Dataset 1 contains the main information for the 
study such as demographic information, information related to treatment and assessment, 
and viral load results. Dataset 2 contains subjects’ characteristics at baseline and 
Intention–To–Treat8 (ITT) exposed population information, and dataset 3 contains 
classification of type of failure or success information at week 24.                       
 
After selecting variables for analysis, these datasets were combined into one. The original 











8 “Intention to treat” is a strategy for the analysis of randomised controlled trials that compares patients in 
the groups to which they were originally randomly assigned. This is generally interpreted as including all 
patients, regardless of whether they actually satisfied the entry criteria, the treatment actually received, and 





Table 1.1: List of variables and Attributes of dataset 1:  
 
Categories Variable Name Description 
Subject and Demographic information 
(PI resistant is classifying subject 
according to whether their virus is 
resistant to Protease Inhibitor (PI) which 
is the class that the study drug belongs 
to): 
SUBJID Subject ID 
AGE Age in years 
SEX Sex 
RACECD Race code 
RACE Race 
ATRTCD Actual treatment code 
atrtgrp Actual treatment group 
Visit name and code, number of days 
since treatment start date and date for 
each assessment 
AVISIT Actual visit description 
AVISNUM Actual visit sequence number 
LBACTDY Actual study day of collection 
LBDT Actual date of collection 
Whether the assessment prior to 
treatment start date or post treatment 
stop date 
ATTYPECD Time in relation to treatment - code 
ATTYPE Time in relation to treatment 
Viral Load results (with units, logs and 
change from BL and assay information) 
LBORUNIT Original unit 
LBORRES Original text result 
LBORRESN Original numeric result 
LBORCHBL Change from baseline - original unites 
LBORRLG Original numeric result - 10log  
LBORRLGC Change from baseline - 10log  
ASSAYV Assay version 
ASSAYVCD Assay version code 
LLOD Lower level of detection 
ULOD Upper level of detection 
KEEPLOD Retained <or> LOD valid value flag 
Viral load results in the situation where 
there are several values for the same 
visit window with the appropriate flag 
LBEVFLG Evaluable flag 
LBORRSNW Windowed original numeric result 
LBORRLGW Windowed 10log original numeric result 
LBORLGCW Windowed change from baseline - 10log  
 
 
Table 1.2: List of variables and Attributes of dataset 2:  
 
Attribute Variable Name Label 
Subject characteristics at 
baseline and ITT exposed 
population 
SUBJID Subject ID 
ACT20GCD Actual introduction of a dose of T20 (yes/no) code 
ACT20GRP Actual introduction of a dose of T20 (yes/no) 
BLVLGCD Baseline viral load subgroup code 
BLVLGRP Baseline viral load subgroup 
CD4CG2CD CD4+ cells/cu mm group 2 code 
CD4CGRP2 CD4+ cells/cu mm group 2 
MULPICD2 Number of multi-PI mutations code 
MULPIG2 Number of multi-PI mutations group 
REGION Region of recruitment 
PNITTE Intent-to-Treat Exposed population 
CD4__BLC Baseline CD4+ cell count 
CD4__BLQ Baseline CD4+ cell percentage 
CD8__BLC Baseline CD8+ cell count 








Table 1.3: List of variables and Attributes of dataset 3:  
 
Attribute Variable Name Label 
Subject number and visit name and 
code 
SUBJID Subject ID 
AVISIT Actual visit description 
AVISNUM Actual visit sequence number 
Response at week 24 (has the subject 
managed to get below 400 copies/mL) 
according to 2 algorithms: “Observed” 
and “Time to Loss of Virological 
Response” 
P400_OBS <400 copies/mL 
P400_TLO <400 copies/mL, TLOVR 
Detailed classification of type of failure 
at week 24 
r400_tlc Reason for failure code 
r400_tl Reason for failure 
 
 
3.1.2 Data Processing 
Some values such as negative study days, i.e. AVISIT= “Screening”, and the repeated first 
day measurement, i.e. AVISIT= “Day 1”, and also re-test measurement on the same day, 
i.e. LBEVFLG9 = “0” and KEEPLOD10 = “0”, were eliminated for presenting summary 
statistics which means it allows us to select one observation per subject per visit. In 
addition, all the missing cases of LBEVFLG and KEEPLOD are also excluded. Also, to 
model viral decay, using ATTYPE, all the measurements where the value does not equal 
“Treatment” were excluded, e.g. drop pre-treatment measurements.  
 
Some patient’s Plasma HIV-1 RNA was repeatedly quantified beyond 24 weeks, i.e. by 32 
or 40 weeks, and the values by 24 weeks are only used for the analysis. 
 
9 This flag allows our group to select 1 observation per subject per visit for presenting summary statistics.  In 
particular, if there are 2 assessments for the same visit “window”, they will take the closest to the target date 
or if they are equidistant, the average value. When selecting observations based on this flag, i.e. LBEVFLG, 
for summary statistics, the “windowed type variables”, i.e. LBORLGCW, LBORRLGW, and LBORRSNW, 
need to be used because these variables include the correct observation or the averaged value when 
applicable. However, for the model part of this project, all assessments need to be used i.e. if several tests 
were carried out for the same visit window, so this aspect can be omitted [31].   
 
10 This flag selects a re-test (on the same day) if the first test reached the limit of detection of the assay, this 
aspect needs to be used for this project (both for summaries and the model part). (Sometimes a test reached 
the limit of detection e.g. <50 and can not be re-tested so this value needs to be kept, hence the reason why 




Original viral load results, such as 10log (original numeric result), i.e. LBORRLG or 
original numeric result, i.e. LBORRESN, are considered as response variables. Also, 
variables for the baseline characteristics, such as variable number of mutations at baseline, 
i.e. MULPICD2; baseline CD4+ cell count, i.e. CD4_BLC; and introduction of T20 
(enfuvirtide, background HIV medication), i.e. ACT20GCD, were considered as 
covariates. Because they are considered as an important part of the description of the study 
population, and ones that are likely to have an impact on the effect of the drug [31]. 
 
Also, to investigate whether the early viral decay rates had an impact on long-term 
response (week 24), the binary response variable indicating viral load measurements 
below the 400 copies/mL threshold at week 24 according to TLOVR, i.e. P400_TLO, was 
used.  
 
3.2 Statistical Methodologies 
Using the NLMIXED procedure in SAS, nonlinear mixed effect models (which have both 
fixed and random effects) were fitted.  
 
Spearman’s rank tests (using the CORR procedure in SAS) performed for the correlation 
of estimated the first-phase viral decay rates11, i.e. 1d , with ‘ 10log (baseline RNA)’ and the 
correlation of 1d with respective ‘week 1, week 20 and week 24 10log  (RNA) change from 
baseline’. The correlation of 1d with ‘baseline CD4+ cell count’ and the correlations of 
‘week 1 10log  (RNA) change from baseline’, i.e. early viral dynamics or week 1 virus load 
reduction, with ‘weeks 20 and 24 10log  (RNA) change from baseline’, i.e. week 20 and 24 
virus load reduction, were performed respectively. 
 




The ANOVA procedure in SAS was performed for age, ethnicity, gender, and the actual 
treatment group effects on the first-phase viral decay rates, respectively. Tukey's 
Studentized Range (HSD) test in GLM was also performed for the actual treatment group 
effects on estimated 1d  viral decay rates. 
 
The Wilcoxon rank sum and Kruskal-Wallis tests (using the NPAR1WAY procedure in 
SAS) was performed for examining properties of actual treatment group on the first-phase 
viral decay rates.  
 
In addition, Univariate Regression Models (GLM) were fitted (using the GLM procedure 
in SAS) to identify baseline characteristics which are correlated with the estimated first-
phase viral decay rates.  
 
The Wilcoxon rank sum and Kruskal-Wallis tests was applied to examine if the early viral 
decay rates can predict the long-term response (24 weeks) and Univariate logistic 
regression analyses (using the CATMOD procedure in SAS) was used to examine if the 
actual treatment group is a significant predictor for the long-term response. 
 
3.3 Software used 
All analyses were conducted in SAS v9.1 (SAS Institute Inc., 2003). The NLMIXED 
procedure and relevant command statements were conducted in SAS, and statistical 
software-R v2.6.2 and SPSS v14.0 (SPSS Institute Inc., 1989-2005) were also used to 





SECTION 4:   RESULTS 
4.1 Complete Dataset Results 
4.1.1 Data Summary 
A total of 116 subjects’ Plasma HIV-1 RNAs were repeatedly quantified and their 
demographic information was provided for the study (dataset 1). This number came from 
an original dataset 2 of 288 subjects. There were 17 (14.7%) females and 99 (85.3%) 
males. Their median age was 43 years (range: 16-65 years). The median baseline CD4 cell 
count was 152 (cells/mm 3 ) and median 10log  (pre-treatment Plasma HIV-1 RNA) was 
4.55. 87 HIV infected patients (75%) were treated with three potent antiviral drugs; does 1 
(30; 25.9%), dose 2 (28; 24.1%) and dose 3 (29; 25.0%) and 29 patients (25%) were in the 
control group.  
 
Plasma HIV-1 RNA was repeatedly quantified on days 1, 2, 3, 8, 10, 15, and weeks 4, 8, 
12, 16, 20, 24, 32 and 40 after initiation of treatment. However, for various reasons such 
as Plasma HIV-1 RNA rebound, never achieved VL suppression by weeks 24, 40 patients 
(34.5%) completed their treatments before 24 weeks as follows: 
 
• 1 patient (0.9%) on 10 days 
• 3 patients (2.6%) on 4 weeks  
• 2 patients (1.7%) on 8 weeks  
• 6 patients (5.2%) on 12 weeks 
• 19 patients (16.4%) on 16 weeks 





76 patients (65.5%) completed their treatments beyond 24 weeks: 
 
• 41 patients (35.3%) on 24 weeks  
• 29 patients (25.0%) on 32 weeks  
• 6 patients (5.2%) on 40 weeks    
 
Of the 116 subjects, 107 were used for the viral dynamic analysis, including the model 
fitting; because 9 subjects had no initial viral decline at all after starting treatment, they are 
ineligible for viral dynamic analysis.  
 
4.1.2 Subjects’ Viral Decay Patterns 
 
Before fitting a model, subjects’ viral decay patterns were examined through plotting the 
data. Primarily, some randomly selected subjects’ viral decay patterns through time after 
they started their treatments were examined. The next fitted plots (figure 4), for 
“windowed” 10log  (original numeric result) through day after starting treatment for each 
randomly selected 7 people show diverse viral decay or rebound patterns, respectively. 
Overall, after the early rapid decay term before approximately 10 days ( 7=t , week 1), 
some subjects’ plasma virus seems to have increased/rebounded (and maintained in that 
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Figure 4:  The fitted curves of each 7 randomly selected patients. The first reference vertical 
dotted line indicates 2 weeks (16 days) and the second reference vertical dotted line indicates 
4 weeks (30 days) which is the end of period Wu et al. (2004) [13] derived viral decay rates. 
 
The subjects were classified as responders or non-responders at a long-term time point (24 
weeks) according to a Time to Loss of Virological Response (P400_TLO) algorithm. 
According to this rule, subjects who discontinued their treatments or viral load never fell 
below 400 copies/mL, i.e. never achieved VL suppression by week 24, or viral load 
rebounded above the threshold, i.e. Plasma HIV-1 RNA rebounded, were classified as 
non-responders. Some subjects of insufficient viral load response, or Protocol mandated 




Specifically, 34 subjects (29.3%) never achieved VL suppression by week 24, 21 subjects’ 
(18.1%) Plasma HIV-1 RNA rebounded, 15 subjects (12.9%) had insufficient viral load 
responses and 18 subjects (15.6%) failed to get below 400 copies/mL at week 24. 10 
subjects’ (8.6%) Protocol mandated switch from 150mg Brecanavir12/ritonavir13 (BCV/r) 
and only 18 subjects (15.5%) were classified as responders at visit and censored thereafter 



















12 Brecanavir, a novel protease inhibitor (PI), has sub-nM in vitro antiviral activity against multi-PI-resistant 
HIV-1 and in vitro is >100-fold more potent than previously marketed PIs and approx. 10-fold more potent 
than the recently marketed PI, darunavir [29]. 
 
13 Ritonavir, also known as Norvir, is a type of medicine called a protease inhibitor (PI). PIs act by blocking 
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Figure 5:  Plots of patients demonstrating (A) responder at visit and censored thereafter, (B) 
Protocol mandated switch from 150mg BCV/r, (C) never achieved VL suppression by week 
24, (D) Plasma HIV-1 RNA rebounded and (E) insufficient viral load response, clockwise 
from top left. The first reference vertical dotted line indicates 2 weeks (16 days) and the 
second reference vertical dotted line indicates 4 weeks (30 days) which is the end of period 








Detailed classification types of each individual plot are presented in figure 6.1- 6.5. 
 
 
Figure 6.1:  The fitted curves from 6 randomly selected patients who were responder at visit 






Figure 6.2:  The fitted curves from 6 randomly selected patients who were Protocol 
mandated switch from 150mg BCV/r. The dots are the observations, and the solid lines are 










Figure 6.3:  The fitted curves from 6 randomly selected patients who never achieved VL 







Figure 6.4:  The fitted curves from 6 randomly selected patients whose plasma HIV-1 RNA 





Figure 6.5: The fitted curves from 6 randomly selected patients demonstrating insufficient 




The following plots (in figure 7) are for “windowed” 10log  (original numeric result) 
through the day after starting treatment, by treatment with three potent antiviral drug 
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Figure 7:  The fitted curves from 30, 28, 29 and 29 patients by actual treatment (A) dose 1, 
(B) dose 2, (C) dose 3 and (D) control group, clockwise from top left. The first reference 
vertical dotted line indicates 2 weeks (16 days) and the second reference vertical dotted line 





4.2 Fitting Nonlinear Mixed Effect Models  
 
4.2.1 Fitting Nonlinear Mixed Effect Single-phase Viral Dynamic Models 
At first, since most of the data show rapid decay patterns from the day of starting 
treatment to approximately 10 days, a nonlinear mixed effect single-phase viral dynamic 




day 2 ( 0=t , the day of starting treatment) to day 16 ( 14=t , 2 weeks) for the next 
model14: 
 
                                   )()]exp()[exp(log)]([log 111010 ttdPtV iii +−=                             (8) 
 
where )(ti  is a HIV-1 RNA measurement error (on the 10log  scale) with a mean of zero, 
and )(tVi is HIV-1 RNA copies/mL plasma at treatment time t  for the i th subject. The 
viral decay rates for the i th subject is ii bdd 111 += , where the fixed-effect parameter, i.e. 
1d  is the population decay rates for the first viral decay phases and ib1  is a random effect 
parameter assumed to be iid ),0( 2bN  , that quantify the between-subject variation of viral 
decay rates. Parameter ii bPP 211 +=  is a macroparameter, with )exp( 1iP being baseline virus 
load at time 0=t  [13, 14, 20, 26, 27]. 
 
To get starting values for the model, a simple nonlinear regression model using the NLIN 
procedure was used: without fitting random factor, the NLIN procedure was used to 
generate appropriate values because the NLMIXED procedure is sensitive to starting 
values.  
 
The model had converged by Gauss-Newton iterative Method, i.e. the residual sum of 
squares decreased until there was no improvement in model fit [Appendix 1, table 2.1]. 
 
 
14 HIV-1 RNA data from day 2 ( ,0=t  the day of starting treatment) to day 10 ( ,7=t  1 week) and day 2 to 
day 30 ( ,28=t  4 weeks) were also considered and fitted to the models (result not shown, the main results 
are consistent with the result of this study). However, 2 weeks dataset were used to derive viral decay rates 
for the adequateness based on the viral decay patterns, because viral rebound occurred after 2 weeks and the 




In the ANOVA table 2.1, the value of the residual sum of squares presents the value that 
the iterative fitting process converged to. The mean square error of the model fit is the 
estimate of variability in the data when adjusted for the non-linear logistic model trend we 
have assumed. The ANOVA table 2.2 is then followed by a table of parameter estimates. 
(In this case, there were 1P  10.488 and 1d  0.169 want to estimate, standard error and an 
asymptotic 95% confidence interval.)  
 









Pr > F 
Model 2 8094.9 4047.5 3715.43 <.0001 
Error 501 545.8 1.0894   












P1 10.4882 0.2001 10.0951 10.8814 
d1 0.1691 0.0222 0.1255 0.2127 
 
 
A nonlinear mixed effect single-phase viral dynamic model with one random effect 
parameter, i.e. ib1 , was fitted after applying the estimated fixed-effect parameter estimates, 
i.e. ,1d 1P , and the mean squared error as starting values (using PROC NLMIXED 
statements) for the 107 subjects. For the Optimization Technique, Dual Quasi-Newton was 
used, and Adaptive Gaussian Quadrature was used as the Integration Method [Appendix 1, 
table 2.2].    
 
The algorithm has converged successfully and the fitting information (table 2.3) lists the 




information criteria of Akaike and corrected Akaike (for small sample sizes) in two 
different forms, i.e. AIC and AICC: 1091.5 and 1091.6, respectively. These statistics can 
be used to compare different nonlinear mixed models. Also, the “Parameter Estimates” 
(table 2.4) lists the maximum likelihood estimates of the four parameters and their 
approximate standard errors computed using the final Hessian matrix [24]. 
 
Table 2.3: Fit Statistics table 
 
Fit Statistics 
-2 Log Likelihood 1083.5 
AIC (smaller is better) 1091.5 
AICC (smaller is better) 1091.6 










Error DF t Value Pr > |t| Alpha Lower Upper Gradient 
P1 10.4761 0.1041 106 100.65 <.0001 0.05 10.2698 10.6825 5.608E-6 
d1 0.1662 0.02473 106 6.72 <.0001 0.05 0.1171 0.2152 2.06E-6 
Error 0.5406 0.01918 106 28.19 <.0001 0.05 0.5025 0.5786 -0.00002 




Using the fixed-effect parameter estimates, i.e. ,1d 1P , the mean squared error, and 
variance component of ib1  as starting values, a nonlinear mixed effect single-phase viral 
dynamic model with two random effect parameters, i.e. ib1 , iP1 , was fitted (using PROC 
NLMIXED statements) for the same subjects.    
 
The algorithm has converged successfully and the final maximized value of the log 
likelihood, i.e. -2 log likelihood, was 768.3, AIC and AICC were 780.3 and 780.5, 




1P , the mean squared error, covariance of ib1 and ib2  (which is not significant in the result), 
and variance of ib1 , ib2  respectively, and also their approximate standard errors are listed 











DF t Value Pr > |t| Alpha Lower Upper Gradient 
P1 10.4925 0.1756 105 59.76 <.0001 0.05 10.1443 10.8406 0.001018 
d1 0.1684 0.01524 105 11.05 <.0001 0.05 0.1382 0.1986 0.006712 
error 0.3007 0.01252 105 24.02 <.0001 0.05 0.2759 0.3255 0.002293 
varcomp11 0.02003 0.003425 105 5.85 <.0001 0.05 0.01323 0.02682 -0.00064 
varcomp12 -0.03959 0.02775 105 -1.43 0.1568 0.05 -0.09462 0.01545 -0.00134 





4.2.2 Fitting Nonlinear Mixed Effect Biphasic Viral Dynamic Models 
Rapid decay pattern (from the day of starting treatment to approximately 10 days) and 
slow decay pattern are observed in the same dataset, i.e. HIV-1 RNA data from day 2 
( 0=t , the day of starting treatment) to day 16 ( 14=t , 2 weeks). With the data, a nonlinear 
mixed effect biphasic viral dynamic model (7) was fitted next.  
 
Also, to get starting values for the model, a simple nonlinear regression model for the 
biphasic of model (using PROC NLIN statement) was used with the arbitrary initial values 
for fixed effect parameters without fitting random factors. Then, a biphasic model with 
two random effect parameters; 1d , 1P  was fitted using the estimated fixed-effect parameter 
estimates; 1d , 1P , 2d , 2P  and the mean squared error. The algorithm has converged 




error, covariance of ib1 and ib3  (which is not significant in the result), variance of ib1 and 
ib3 , are given the “Parameter Estimates” table 2.6. 
 
 






DF t Value Pr > |t| Alpha Lower Upper Gradient 
P1 10.1026 0.2630 83 38.41 <.0001 0.05 9.5795 10.6257 -1.76E-6 
P2 9.6232 0.6032 83 15.95 <.0001 0.05 8.4235 10.8230 -5.09E-6 
d1 0.1691 0.01812 83 9.33 <.0001 0.05 0.1330 0.2051 0.000557 
d2 0.8850 0.2497 83 3.54 0.0006 0.05 0.3884 1.3816 0.000027 
error 0.2868 0.01340 83 21.40 <.0001 0.05 0.2602 0.3135 -0.00024 
varcomp11 0.01885 0.003801 83 4.96 <.0001 0.05 0.01129 0.02641 -0.00166 
varcomp13 0.05282 0.04726 83 1.12 0.2669 0.05 -0.04117 0.1468 0.000028 




Using approximate values of estimated fixed and random effect parameters from the 
previous model, a biphasic model with three random effects was fitted next with zero 
covariance components. (For the variance of 2d , parameter value searching function in 
NLMIXED was used.) The algorithm has converged successfully, and the fitting 
information table lists the final maximized value of the log likelihood, i.e. -2 log 
likelihood 735.0, AIC and AICC: 751.0 and 751.3, respectively [Appendix 1, table 2.3]. 
Also, the “Parameter Estimates” table 2.7 lists the maximum likelihood estimates of the 
eight parameters; 1d , 1P , 2d , 2P , the mean squared error, variance of ib1 , ib2 and ib3  

























DF t Value Pr > |t| Alpha Lower Upper Gradient 
P1 10.1761 0.2129 104 47.80 <.0001 0.05 9.7539 10.5982 0.000668 
P2 11.2454 0.5086 104 22.11 <.0001 0.05 10.2369 12.2539 -0.00147 
d1 0.1423 0.01511 104 9.42 <.0001 0.05 0.1124 0.1723 -0.0029 
d2 1.7727 0.2487 104 7.13 <.0001 0.05 1.2796 2.2658 0.003581 
error 0.2776 0.01178 104 23.57 <.0001 0.05 0.2542 0.3009 0.006208 
varcomp11 0.01928 0.003195 104 6.04 <.0001 0.05 0.01295 0.02562 0.071378 
varcomp22 0.1934 0.06813 104 2.84 0.0055 0.05 0.05826 0.3285 -0.00593 
varcomp33 4.3740 0.6899 104 6.34 <.0001 0.05 3.0058 5.7422 -0.00021 
 
 
Since the biphasic model with three random effects and zero covariance components was 
successfully converged, using previous estimated initial parameter values, the same model 
with covariance components was fitted next. (For the variance of 2d , parameter value 
searching function in NLMIXED was used also.) The algorithm has converged 
successfully and the fitting information table lists the final maximized value of the log 
likelihood, i.e. -2 log likelihood 702.8, AIC and AICC: 724.8 and 725.3, respectively 
which are slightly better than the previous model (table 2.8). (Model diagnoses support 
this result [Appendix 1, table 2.4- 2.5]). Also, the “Parameter Estimates” (table 2.9) lists 
the maximum likelihood estimates of the eleven parameters; 1d , 1P , 2d , 2P , the mean 
squared error, variance of ib1 , ib2 and ib3  respectively, covariance of ib1 and ib2 (which is not 




Table 2.8: Fit Statistics for both models 
 
Fit Statistics 
 The single-phase model The biphasic model 
-2 Log Likelihood 768.3 702.8 
AIC (smaller is better) 780.3 724.8 
AICC (smaller is better) 780.5 725.3 













Error DF t Value Pr > |t| Alpha Lower Upper Gradient 
P1 9.5657 0.2278 104 41.98 <.0001 0.05 9.1139 10.0176 0.000304 
P2 13.3343 0.2344 104 56.89 <.0001 0.05 12.8695 13.7992 0.00027 
d1 0.09568 0.01432 104 6.68 <.0001 0.05 0.06729 0.1241 0.001695 
d2 1.7545 0.1488 104 11.79 <.0001 0.05 1.4594 2.0496 0.000999 
error 0.2615 0.01443 104 18.11 <.0001 0.05 0.2328 0.2901 0.003725 
varcomp11 0.01090 0.003285 104 3.32 0.0012 0.05 0.004389 0.01742 0.015094 
varcomp22 0.7450 0.1586 104 4.70 <.0001 0.05 0.4306 1.0595 -0.00055 
varcomp33 2.7611 0.4880 104 5.66 <.0001 0.05 1.7933 3.7288 0.000469 
varcomp13 -0.09803 0.03071 104 -3.19 0.0019 0.05 -0.1589 -0.03713 0.006636 
varcomp23 -1.0988 0.2269 104 -4.84 <.0001 0.05 -1.5487 -0.6488 0.000382 









4.3 Analysis Results from the Models 
4.3.1 Initial Viral Decay Rates 
The estimated first-phase decay rates, i.e. 1d  from individual subjects (the empirical 
Bayesian estimates) of the nonlinear mixed effect single-phase and biphasic viral dynamic 
models are summarized for different ages, ethnicities and actual treatment groups in the 
table 4.1 and 4.2.  




15 It had not converged using alterative methods for the convergence. However, since we are interested in the 
first-phase viral decay rates rather than the other phase viral decay rates (for the multi-phase model), and we 
obtained the values with other main random effects of the biphasic model, it seems that it is not a principle 





Table 4.1: Summary of estimated viral decay rates of the nonlinear mixed effect single-phase viral 
dynamic model.                                 
 
Characteristic Label 
Decay rate,  
Mean d1  SD 
Phase1 
Total (n=107) 0.168  0.129 
Treatment regimen 
dose1 (n=28) 0.182  0.127 
dose2 (n=28) 0.212  0.124 
dose3 (n=29) 0.193  0.126 
control (n=22) 0.063  0.085 
Age range, years 
Less than 20 (n=7) 0.180  0.123 
30-34 (n=5) 0.184  0.129 
35-39 (n=22) 0.181  0.122 
40-44 (n=31) 0.162  0.149 
45-49 (n=18) 0.185  0.125 
50-59 (n=20) 0.119  0.112 




Heritage and Arabic/North 
African Heritage (n=87) 
0.161  0.126 
African American/African 
Heritage (n=20) 





Table 4.2: Summary of estimated viral decay rates of the nonlinear mixed effect biphasic viral dynamic 
model.                                 
 
Characteristic Label 
Decay rate,  
Mean d1  SD 
Phase1 Phase2 
Total (n=107)  0.097  0.095 1.681  0.810 
Treatment regimen 
dose1 (n=28) 0.114  0.096 1.872  0.915 
dose2 (n=28) 0.128  0.091 1.690  0.841 
dose3 (n=29)  0.109  0.089 1.412  0.520 
control (n=22) 0.022  0.072 1.779  0.90 
Age range, years 
Less than 20 (n=7) 0.112  0.101 1.920  1.155 
30-34 (n=5) 0.119  0.109 2.252  1.336 
35-39 (n=22) 0.103  0.092 1.540  0.805 
40-44 (n=31) 0.092  0.109 1.660  0.718 
45-49 (n=18) 0.109  0.093 1.545  0.827 
50-59 (n=20) 0.062  0.073 1.729  0.717 




Heritage and Arabic/North 
African Heritage (n=87) 
0.093  0.095 1.710  0.856 
African American/African 
Heritage (n=20) 





4.3.2 Baseline Characteristics 




Table 5: Baseline characteristics of study participants by actual treatment group for the completed dataset.    














Female 17 (14.7) 3 9 4 1 
Male 99 (85.3) 26 21 24 28 
Age range, years, no.(%) 
Less than 20 7 (6.0) 1 2 2 2 
30-34 5 (4.3) 2 2 1 0 
35-39 22 (19.0) 2 5 7 8 
40-44 36 (31.0) 13 7 5 11 
45-49 20 (17.2) 3 8 5 4 
50-59 22 (19.0) 8 6 5 3 




20 (17.2) 6 4 2 8 
White – 
White/Caucasian/European 
Heritage and Arabic/North 
African Heritage 




25th percentile 3.89 4.17 3.49 3.67 4.36 
Median 4.55 4.36 4.57 4.31 4.63 
75th percentile 5.17 5.45 5.09 5.18 5.00 
CD4 cell count, 
cells/mm3 
25th percentile 53.5 23 62 60.5 101 
Median 152 69 180.5 190.0 155 
75th percentile 281.5 175 337 325.5 280 
CD4 cells, % 
25th percentile 6.5 5 9 8 10 
Median 13 7 16.5 13 13 
75th percentile 19 13 25 22 17 
 
ANOVA (1-way analysis of variance) analysis showed the effects of  “age”, “gender” 
and “ethnicity” on the first-phase viral decay rates of both models were not 
significant: p=0.733, p=0.257 and p=0.420  respectively for the single-phase model, 
and p=0.812,  p=0.192 and p=0.593 respectively for the biphasic. (This result was 
marginally confirmed by Univariate Regression Analyses treating age, gender, and 
ethnicity as continuous covariates). However, there was a marginally significant 
difference among “actual treatment groups” for both models (p=0.0001 and 




Results of the Wilcoxon rank sum and Kruskal-Wallis tests indicated that the first-phase 
viral decay rate in the control group (mean SDd 1 , 0.063 0.085 and 0.022 0.072 for 
the single and biphasic model, respectively) is significantly lower than in other treatment 
groups, i.e. dose 2 (mean SDd 1 , 0.212  0.124 and 0.128  0.091 for the single and 
biphasic model, respectively), dose 1 (mean SDd 1 , 0.182 0.127 and  0.114 0.096, 
respectively), and dose 3 (mean SDd 1 , 0.193 0.126 and 0.109 0.089, respectively), 
for both models (p=0.0002 and p=0.0005, respectively) [Appendix 1, table 3.5.1- 3.6.8]. 
The first-phase decay rates in dose 2 was higher than other groups, but there were no 
significant differences among three treatment groups according to Tukey's Studentized 
Range (HSD) in GLM for the both models [Appendix 1, table 3.7.1- 3.7.2].  In addition, 
the regression analysis confirmed that treatment assignment was a significant predictor for 
the first-phase viral decay rates, i.e. 1d  in both models (p=0.002 and p=0.001 respectively). 
 
Multiple (Covariate) Regression Analyses (GLM), including the covariates baseline HIV-
1 RNA levels, baseline CD4+ counts, age, ethnicity and gender of patients, number of 
mutations at baseline, introduction of T20 and treatment assignment, indicated that 
‘treatment assignment’, and ‘number of mutations at baseline’ were significant predictors 
(p=0.014 and p=0.0023, respectively) of the first-phase viral decay rates for the single-
phase model. In addition, ‘baseline HIV-1 RNA levels’, ‘treatment assignment’ and 
‘number of mutations at baseline’ were significant predictors of 1d  (p=0.005, p=0.02 and 
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Figure 8.1:  The correlation between the first-phase viral decay rates and baseline HIV-1 
RNA levels at t=0 for the nonlinear mixed effect single-phase viral dynamic model. The 
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Figure 8.2:  The correlation between the first-phase viral decay rates and baseline HIV-1 
RNA levels at t=0 for the nonlinear mixed effect biphasic viral dynamic model. The 




Figure 8.1- 8.2 show the correlation of the first-phase viral decay rates, i.e. 1d  with 
baseline HIV-1 RNA levels for the two models. 1d  were somewhat negatively correlated 
with baseline virus load (r = -0.292, p=0.002) and (r = -0.414, p<0.0001) for the both 
models respectively [Appendix 1, table 3.9.1- 3.9.2] and positively correlated with 
baseline CD4+ cell counts (r = 0.428, p<0.001) and (r = 0.482, p<0.001) for the both 
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Figure 9.1:  The correlation between the first-phase viral decay rates and week 1 virus load 
reduction from baseline for the single-phase viral dynamic model (for instance, 3 indicates 
10log viral load reduction from baseline whereas, -1 indicates 10log viral load increase from 
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Figure 9.2:  The correlation between the first-phase viral decay rates and week 1 virus load 
reduction from baseline for the single-phase viral dynamic model (for instance, 3 indicates 
10log viral load reduction from baseline whereas, -1 indicates 10log viral load increase from 
baseline.). The correlation coefficient and P value from Spearman’s rank tests are given. 
 
 
Also, the strong positive correlations (r = 0.867, p<0.0001 and r = 0.852, p<0.0001) 
between week 1 virus load reduction, i.e. early virus dynamics, and the first-phase viral 
decay rates for both models were observed (figure 9.1- 9.2) [Appendix 1, table 3.11.1- 
3.11.2].  
 
In addition, there were positive correlations (r = 0.415, p=0.0003 and r = 0.432, p=0.002, 
respectively) between week 20 and 24 virus load reduction and the first-phase viral decay 
rates for the single-phase model. Also, there were positive correlations (r = 0.346, p=0.003 
and r = 0.394, p=0.006, respectively) between week 20 and 24 virus load reduction and the 




than those of week 1 virus load reduction [Appendix 1, table 3.12.1- 3.12.4]. Also, week 
1 virus load reduction, i.e. early viral dynamics, and week 20 and 24 virus load reduction 
have positive correlations (r = 0.445, p<0.0001 and r = 0.420, p=0.003, respectively) for 
both models [Appendix 1, table 3.13.1- 3.13.4]. Similarly, it is observed that the 
individuals with higher first-phase viral decay rates, i.e. subjects with 1d  > 0.168 (mean of 
1d  for the single-phase model), were more likely to have suppressed virus load at week 20 
(mean SDd 1 , 2.7431.172) and at week 24 (2.560.996) than the other subjects with 
1d   0.168 (3.701 1.164 at week 20 and 3.510 1.313 at week 24, respectively) for the 
single-phase model. Consistently, the individuals with higher first-phase viral decay rates, 
i.e. subjects with 1d  > 0.097 (mean of 1d  for the biphasic model), were also more likely to 
have suppressed virus load at week 20 (2.722 1.166) and at week 24 (2.503 0.987)  than 
the other subjects with 1d   0.097 (3.818  1.102 at week 20 and 3.692  1.234 at 24 
week) for the biphasic model [Appendix 1, table 3.14.1- 3.14.8].  
 
The subjects with higher first-phase viral decay rates were also more likely to show a 
smaller number of mutations at baseline than the other subjects in both models [Chart 1.1-
1.2]. 
Number of multi-PI mutations at baseline
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Chart 1.1:  Number of multi-PI mutations at baseline by the first-phase viral decay rates for 
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Chart 1.2:  Number of multi-PI mutations at baseline by the first-phase viral decay rates for 




4.3.3 Initial Viral Decay Rates and Long-Term Response 
Among the 107 subjects tested for in this study, 81 were classified as virological non-
responders, and 26 were classified as responders (P400_TLO). The viral decay rates 
between the virological responders and non-responders using the Wilcoxon rank sum and 
Kruskal-Wallis tests (using the NPAR1WAY procedure in SAS) was performed 
[Appendix 1, table 3.15.1- 3.15.6]. It was found that the first-phase viral decay rates in 
responders (mean SDd 1 , 0.267  0.103) were significantly higher (both p<0.001 
respectively) than those in non-responders (mean SDd 1 , 0.137  0.121) in the single-
phase model. Also, the first-phase viral decay rates in responders (mean SDd 1 , 
0.171  0.073) were significantly higher (both p<0.001 respectively) than those in non-
responders (mean SDd 1 , 0.0740.09) in the biphasic model.  
 
The subjects with higher first-phase viral decay rates were more likely to be responders. 
For example, if 1d > 0.168 (mean of 1d for the single-phase model), 20 (40.0%) of 50 were 




model. Also, if 1d > 0.097 (mean of 1d for the biphasic model), 21 (39.62%) of 53 were 
responders and 1d   0.097, only 5 (9.30%) of 54 were responders) for the biphasic model 
[Appendix 1, table 3.16.1- 3.16.2]. 
 
The week 1 virus load reduction in the responder group was also higher (mean SDd 1 , 
1.3230.689) than that in the non-responder group (mean SDd 1 , 0.6140.675) for both 
models identically. The differences were statistically significant (p<0.0001) for the 
Wilcoxon rank sum and Kruskal-Wallis tests for both models [Appendix 1, table 3.17.1- 
3.17.6].  
 
In addition, Univariate Logistic Regression analyses (using the CATMOD procedure in 
SAS) showed that the control group was a significant predictor for 24 weeks virological 













SECTION 5:   DISCUSSION  
The purpose of this project was to model viral decay rates, and check the validity of the 
model for the set of data and investigate if the relationships found with baseline covariates 
and long-term response were consistent with Wu et al.’s (2004) findings [13]. 
 
The Nonlinear Mixed Effect Single and Biphasic Viral Dynamic Models for the HIV data 
were fitted using PROC NLMIXED statement in SAS. And the first-phase viral decay 
rates for each subject for both models were derived. Baseline characteristics which were 
correlated with the viral decay rates were identified, and whether the initial, i.e. the first-
phase, viral decay rates can predict long-term response was examined along with other 
relevant analyses.  
 
5.1 Actual Treatment Group for the Viral Decay Rates 
The results indicate that the actual treatment groups were more potent, i.e. higher first-
phase viral decay rates than control group. However, there were no significant differences 
among treatment groups, dose 1, 2 and 3. (This was consistent with the result without 
control group in the data.)  
 
There were no significant differences in the first-phase viral decay rates for different ages, 
ethnicities, and gender groups. The actual treatment effect and the number of multi-PI 
mutations at baseline had impact on the first-phase viral decay rates for the single-phase 
model. Also, the actual treatment effect, baseline HIV-1 RNA levels and the number of 




biphasic model. Besides, the first-phase viral decay rates were somewhat positively 
correlated with baseline CD4+ cell counts in both models.  
 
5.2 Initial Viral Decay Rates and Viral Load Reduction 
The first-phase viral decay rates were somewhat negatively correlated with the baseline 
HIV-1 RNA levels for both models (r = -0.292, p=0.002 and r = -0.414, p<0.0001, 
respectively). These negative correlations confirm the results of Wu et al. [41, 42, 20, 13], 
but differs from the results of Wu et al. (2004) [13] (r = 0.44, p<0.001). Based on the 
equations (6), three possible explanations for this negative correlation between the first-
phase viral decay rates and baseline viral load were derived by Wu et al. (2003) [20]. 
However, the biological mechanisms behind these correlations are considered still unclear 
[13]. Wu et al. (2004) [13] guessed that the direction of the correlation may depend on 
many factors such as the potency of treatment regimens, pretreatment virus production: 
clearance ratio, and turnover rate of infected cells [44, 13].  
 
In addition, strong correlations between the first-phase viral decay rates and week 1 virus 
load reduction from baseline were observed from both models (r = 0.867, p<0.0001 and r 
= 0.852, p<0.0001, respectively). This result consists with the findings of Wu et al. (2004) 
[13] (r = 0.89, p<0.001). There was positive correlation between week 20 and 24 virus 
load reduction and the first-phase viral decay rates for both models. However, their 
correlations were less than those of week 1 virus load reduction. It seems that the week 1 
virus load reduction could be used to replace more complex viral decay rates for the 
assessment of the potency of antiretroviral regimens [13]. Wu et al. (2004) [13] suggested 
this simplification can avoid complicated viral dynamic model fitting and frequent clinical 




the week 1 virus load reduction, a larger number of subjects (sample size) may be required 
[13, 40]. 
 
Individuals with higher viral decay rates were likely to show long-term viral load 
suppression (week 20 and 24 virus load reduction). Also, individuals with higher week 1 
virus load reduction, i.e. early viral dynamics, were more likely to have suppressed virus 
load at week 24, which suggests that the antiviral potency or the initial viral decay rates 
are predictive of long-term viral load response [13]. 
 
5.3 Approaching NLMIXED Models  
The Nonlinear Mixed Effect Viral Dynamic Model can easily handle unbalanced repeated 
and continuous measurements data on each of individuals when interest focuses on 
individual-specific characteristics and allows for flexible variance-covariance and non-
independent error structures of the response vector, whereas GEEs are only feasible for the 
linear in their parameters.  
 
However, the model fitting with the fixed and random effects entering nonlinearly is not 
easy to implement frequently, since standard likelihood approaches are considered much 
more difficult to implement than the linear mixed models16. Also, it seems to be very 
sensitive for initial values. This is not a surprising thing when we consider the data 
repeatedly and continuously measured from various among individuals, and individuals’ 
responses all follow a similar functional form in the model (although it has parameters that 
vary among individuals). Changing the initial values or sectional iteration searching 
method for the initial values can be used, the work is sometimes not trivial and even after 
 





finding the adequate values, and quite a lot of time is required for the complex models 
which contain many parameters or a large dataset.  
 
In general, there are some suggestions for the difficulties or filatures in converging. They 
are as follows: Rescale the data and model so that all parameters are of the same order of 
magnitude for the stability of the algorithm. Otherwise, use boundary constraints to avoid 
the region where overflows may happen, or delete outlying observations which are 
reasonable. Also, if the convergence criterion appears to be descending favourably, it 
might be needed to increase the maximum number of iterations using MAXITER=option 
in SAS NLINMIX procedure. Changing starting values by using a grid search 
specification or changing the optimization technique using TECH=option in SAS 
NLINMIX, and skipping RANDOM before getting accurate starting values can also be 
useful17 [11]. For the long run times, it is important to check whether the model is 
specified correctly. The scaled parameters with same order of magnitude, and the data 
reasonably match the model are required because ill-posed or miss-specified models can 
cause the algorithms to use more extensive calculations designed to achieve convergence 
[11].  
  
5.4 Conclusions and Suggestions 
 
The Nonlinear Mixed Effect Single and Biphasic Viral Dynamic Models for the HIV data 
were fitted using the NLMIXED procedure in SAS. The main findings with the initial 
viral decay rates, i.e. the first-phase viral decay rates, from the models were almost 
identical. For the model comparison aspect, the biphasic viral dynamic model seems 
 
17 Besides, for SAS NLINMIX macro procedure, using of OPTION=SKIPNLIN, TOL= options, trying 
RIDGE=option instead of PROC MIXED itself, and using EXPAND=ZERO option but when 
EXPAND=EBLUP option, also trying GAUSS=, MAXSUBIT=, FRACTION=, and SUBCONV=options 




slightly better in terms of the Akaike information criterion (AIC) and the Bayesian 
information criterion (BIC) in this study. 
 
Further studies could focus on model fitting using Generalised additive models (GAMs) 
with splines which consist of individual segments that are joined smoothly. A GAM is 
defined as a Generalized Linear Model (GLM) with a linear predictor involving a sum of 
smooth functions of covariates. It consists of a random component, an additive component 
and a link function relating the two [45]. Compare than traditional parametric modeling 
tools such as linear or nonlinear regression, the methodology behind the GAM procedure 
has greater flexibility. It relaxes the usual parametric assumption and enables us to 
uncover structure in the relationship between the independent variables and the dependent 
variable [50]. However, this increased flexibility can reduce the interpretability of the 
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Chart 2.1: Column chart for classification of type of failure/success at week 24 by sex. 















Never achieved VL suppression by Week 24 (n=34)
Plasma HIV-1 RNA rebound (n=21)
Insufficient viral load response (n=15)
Others (failure)  (n=18)
Responder at visit,censored thereafter (n=18)
Protocol mandated switch from 150mg BCV/r (n=10)







Chart 2.2: Column chart for classification of type of failure/success at week 24 by ethnic origin. 















Never achieved VL suppression by Week 24 (n=34)
Plasma HIV-1 RNA rebound (n=21)
Insufficient viral load response (n=15)
Others (failure)  (n=18)
Responder at visit,censored thereafter (n=18)
Protocol mandated switch from 150mg BCV/r (n=10)
Total    (n=116)
White - White/Caucasian/European Heritage
(n=95) and Arabic/North African Heritage (n=1)



















































































Never achieved VL suppression by Week 24
(n=34)
Plasma HIV-1 RNA rebound (n=21)
Insufficient viral load response (n=15)
Others  (failure)  (n=18)
Responder at visit,censored thereafter (n=18)
Protocol mandated switch from 150mg BCV/r
(n=10)


































Data Set WORK.DATA16DAYS 
Dependent Variable LBORRLG 
Distribution for Dependent Variable Normal 
Random Effects b1 
Distribution for Random Effects Normal 
Subject Variable SUBJID 
Optimization Technique Dual Quasi-Newton 








Iter P1 d1 
Sum of 
Squares 
0 1.0000 1.0000 25802.7 
1 10.4882 0.1691 545.8 













-2 Log Likelihood 735.0 
AIC (smaller is better) 751.0 
AICC (smaller is better) 751.3 








































Squares Mean Square F Value Pr > F 
Model 31 0.44641255 0.01440040 0.82 0.7326 
Error 75 1.32453849 0.01766051   








Squares Mean Square F Value Pr > F 
Model 31 0.22688636 0.00731891 0.75 0.8115 
Error 75 0.73122736 0.00974970   








Squares Mean Square F Value Pr > F 
Model 1 0.02164941 0.02164941 1.30 0.2569 
Error 105 1.74930163 0.01666002   











Squares Mean Square F Value Pr > F 
Model 1 0.01547787 0.01547787 1.72 0.1920 
Error 105 0.94263586 0.00897748   









Squares Mean Square F Value Pr > F 
Model 2 0.02932355 0.01466178 0.88 0.4197 
Error 104 1.74162748 0.01674642   









Squares Mean Square F Value Pr > F 
Model 2 0.00958037 0.00479019 0.53 0.5930 
Error 104 0.94853335 0.00912051   









Squares Mean Square F Value Pr > F 
Model 3 0.32256405 0.10752135 7.65 0.0001 
Error 103 1.44838699 0.01406201   









Squares Mean Square F Value Pr > F 
Model 3 0.16197366 0.05399122 6.99 0.0003 
Error 103 0.79614007 0.00772952   













Table 3.5.1: Wilcoxon Scores (Rank Sums) table for the single-phase model 
 
Wilcoxon Scores (Rank Sums) for Variable Pred 










2 28 1815.0 1512.0 141.095712 64.821429 
1 28 1596.0 1512.0 141.095712 57.000000 
3 29 1734.0 1566.0 142.681463 59.793103 





Table 3.5.2: Wilcoxon Scores (Rank Sums) table for the biphasic model 
 
Wilcoxon Scores (Rank Sums) for Variable Pred 










2 28 1775.0 1512.0 141.095712 63.392857 
1 28 1661.0 1512.0 141.095712 59.321429 
3 29 1695.0 1566.0 142.681463 58.448276 










Asymptotic Pr >  Chi-Square 0.0002 











Asymptotic Pr >  Chi-Square 0.0005 

















Table 3.6.1: Mean of first-phase viral decay rates of dose 1 group for the single-phase model 
 
 
Basic Statistical Measures 
Location Variability 
Mean 0.182450 Std Deviation 0.12727 
Median 0.215252 Variance 0.01620 
Mode . Range 0.39265 





Table 3.6.2: Mean of first-phase viral decay rates of dose 2 group for the single-phase model 
 
 
Basic Statistical Measures 
Location Variability 
Mean 0.212025 Std Deviation 0.12417 
Median 0.258296 Variance 0.01542 
Mode . Range 0.48697 





Table 3.6.3: Mean of first-phase viral decay rates of dose 3 group for the single-phase model 
 
 
Basic Statistical Measures 
Location Variability 
Mean 0.193033 Std Deviation 0.12603 
Median 0.195224 Variance 0.01588 
Mode . Range 0.44519 





Table 3.6.4: Mean of first-phase viral decay rates of dose 4 group for the single-phase model 
 
 
Basic Statistical Measures 
Location Variability 
Mean 0.062623 Std Deviation 0.08451 
Median 0.047161 Variance 0.00714 
Mode . Range 0.34973 

















Table 3.6.5: Mean of first-phase viral decay rates of dose 1 group for the biphasic model 
 
 
Basic Statistical Measures 
Location Variability 
Mean 0.113850 Std Deviation 0.09562 
Median 0.127144 Variance 0.00914 
Mode . Range 0.28513 






Table 3.6.6: Mean of first-phase viral decay rates of dose 2 group for the biphasic model 
 
 
Basic Statistical Measures 
Location Variability 
Mean 0.127813 Std Deviation 0.09049 
Median 0.163327 Variance 0.00819 
Mode . Range 0.35659 






Table 3.6.7: Mean of first-phase viral decay rates of dose 3 group for the biphasic model 
 
 
Basic Statistical Measures 
Location Variability 
Mean 0.109193 Std Deviation 0.08857 
Median 0.113465 Variance 0.00784 
Mode . Range 0.28308 






Table 3.6.8: Mean of first-phase viral decay rates of dose 4 group for the biphasic model 
 
 
Basic Statistical Measures 
Location Variability 
Mean 0.022183 Std Deviation 0.07190 
Median 0.019937 Variance 0.00517 
Mode . Range 0.30368 










Table 3.7.1: Tukey's Studentized Range (HSD) Test for the actual treatment group in the single-phase model 
 
 







Confidence Limits  
dose 2 - dose 3 0.01995 -0.01690 0.05681  
dose 2 - dose 1 0.03075 -0.00637 0.06788  
dose 2 - contro 0.15171 0.11133 0.19208 *** 
dose 3 - dose 2 -0.01995 -0.05681 0.01690  
dose 3 - dose 1 0.01080 -0.02598 0.04759  
dose 3 - contro 0.13175 0.09168 0.17182 *** 
dose 1 - dose 2 -0.03075 -0.06788 0.00637  
dose 1 - dose 3 -0.01080 -0.04759 0.02598  
dose 1 - contro 0.12095 0.08064 0.16127 *** 
contro - dose 2 -0.15171 -0.19208 -0.11133 *** 
contro - dose 3 -0.13175 -0.17182 -0.09168 *** 







Table 3.7.2: Tukey's Studentized Range (HSD) Test for the actual treatment group in the biphasic model 
 







Confidence Limits  
dose 2 - dose 1 0.01547 -0.01296 0.04391  
dose 2 - dose 3 0.01999 -0.00824 0.04822  
dose 2 - contro 0.10704 0.07611 0.13797 *** 
dose 1 - dose 2 -0.01547 -0.04391 0.01296  
dose 1 - dose 3 0.00452 -0.02365 0.03269  
dose 1 - contro 0.09157 0.06069 0.12245 *** 
dose 3 - dose 2 -0.01999 -0.04822 0.00824  
dose 3 - dose 1 -0.00452 -0.03269 0.02365  
dose 3 - contro 0.08705 0.05636 0.11774 *** 
contro - dose 2 -0.10704 -0.13797 -0.07611 *** 
contro - dose 1 -0.09157 -0.12245 -0.06069 *** 
















Table 3.8.1: Type III sums of squares table from GLM analysis for the single-phase model 
 
 
Source DF Type III SS Mean Square F Value Pr > F 
AGE 31 0.21076183 0.00679877 0.59 0.9463 
SEX 1 0.00224574 0.00224574 0.19 0.6606 
RACE 2 0.02524211 0.01262105 1.09 0.3412 
CD4__BLC 1 0.02114137 0.02114137 1.83 0.1806 
LBORRLG 1 0.02894062 0.02894062 2.51 0.1182 
atrtgrp 3 0.13199133 0.04399711 3.81 0.0140 
MULPICD2 1 0.11675334 0.11675334 10.11 0.0023 






Table 3.8.2: Type III sums of squares table from GLM analysis for the biphasic model 
 
 
Source DF Type III SS Mean Square F Value Pr > F 
AGE 31 0.09743283 0.00314299 0.56 0.9624 
SEX 1 0.00065033 0.00065033 0.12 0.7355 
RACE 2 0.00933769 0.00466885 0.83 0.4421 
CD4__BLC 1 0.01232009 0.01232009 2.18 0.1445 
LBORRLG 1 0.04677750 0.04677750 8.28 0.0054 
atrtgrp 3 0.06022835 0.02007612 3.55 0.0190 
MULPICD2 1 0.05811690 0.05811690 10.29 0.0021 







Table 3.9.1: Spearman Correlation Coefficients table of first-phase viral decay rates  
























Spearman Correlation Coefficients, N = 107 
Prob > |r| under H0: Rho=0 


















Table 3.9.2: Spearman Correlation Coefficients table of first-phase viral decay rates  
and log10 baseline RNA for the biphasic model 
 
 
Spearman Correlation Coefficients, N = 107 
Prob > |r| under H0: Rho=0 



















Table 3.10.1: Spearman Correlation Coefficients table of first-phase viral decay rates  
and CD4__BLC for the single-phase model 
 
 
Spearman Correlation Coefficients, N = 107 
Prob > |r| under H0: Rho=0 



















Table 3.10.2: Spearman Correlation Coefficients table of first-phase viral decay rates  
and CD4__BLC for the biphasic model 
 
 
Spearman Correlation Coefficients, N = 107 
Prob > |r| under H0: Rho=0 



















Table 3.11.1: Spearman Correlation Coefficients table of first-phase viral decay rates  
                            and week 1 log10 RNA change from baseline for the single-phase model 
 
 
Spearman Correlation Coefficients, N = 94 
Prob > |r| under H0: Rho=0 



















Table 3.11.2: Spearman Correlation Coefficients table of first-phase viral decay rates 
                     and week 1 log10 RNA change from baseline for the biphasic model 
 
Spearman Correlation Coefficients, N = 94 
Prob > |r| under H0: Rho=0 



















Table 3.12.1: Spearman Correlation Coefficients table for the single-phase model 
 
Spearman Correlation Coefficients 
Prob > |r| under H0: Rho=0 
Number of Observations 






















Table 3.12.2: Spearman Correlation Coefficients table for the biphasic model 
 
Spearman Correlation Coefficients 
Prob > |r| under H0: Rho=0 
Number of Observations 






















Table 3.12.3: Spearman Correlation Coefficients table for the single-phase model 
 
Spearman Correlation Coefficients 
Prob > |r| under H0: Rho=0 
Number of Observations 






















Table 3.12.4: Spearman Correlation Coefficients table for the biphasic model 
 
Spearman Correlation Coefficients 
Prob > |r| under H0: Rho=0 
Number of Observations 










































Table 3.13.2: Spearman Correlation Coefficients table for the biphasic model 
 
Spearman Correlation Coefficients 
Prob > |r| under H0: Rho=0 
Number of Observations 





















Table 3.13.3: Spearman Correlation Coefficients table for the single-phase model 
 
Spearman Correlation Coefficients 
Prob > |r| under H0: Rho=0 
Number of Observations 


















Spearman Correlation Coefficients 
Prob > |r| under H0: Rho=0 
Number of Observations 























Table 3.13.4: Spearman Correlation Coefficients table for the biphasic model 
 
Spearman Correlation Coefficients 
Prob > |r| under H0: Rho=0 
Number of Observations 





















Table 3.14.1: Mean of viral load at 20 week – higher first-phase viral decay group  
for the single-model 
 
Moments 
N 44 Sum Weights 44 
Mean 2.74250455 Sum Observations 120.6702 
Std Deviation 1.17205848 Variance 1.37372108 
Skewness 0.86309756 Kurtosis -0.0578427 
Uncorrected SS 390.008578 Corrected SS 59.0700063 






Table 3.14.2: Mean of viral load at 20 week – lower first-phase viral decay group  
for the single-model 
 
Moments 
N 36 Sum Weights 36 
Mean 3.70135 Sum Observations 133.2486 
Std Deviation 1.16427539 Variance 1.35553719 
Skewness -0.3718013 Kurtosis -0.6894897 
Uncorrected SS 540.643507 Corrected SS 47.4438016 





Table 3.14.3: Mean of viral load at 24 week – higher first-phase viral decay group  
for the single-model 
 
Moments 
N 29 Sum Weights 29 
Mean 2.55901034 Sum Observations 74.2113 
Std Deviation 0.99615883 Variance 0.99233242 
Skewness 0.71551408 Kurtosis -0.8477826 
Uncorrected SS 217.692792 Corrected SS 27.7853077 







Table 3.14.4: Mean of viral load at 24 week – lower first-phase viral decay group  
for the single-model 
 
Moments 
N 22 Sum Weights 22 
Mean 3.51029091 Sum Observations 77.2264 
Std Deviation 1.31322081 Variance 1.72454888 
Skewness -0.2112281 Kurtosis -1.4838382 
Uncorrected SS 307.302656 Corrected SS 36.2155265 






Table 3.14.5: Mean of viral load at 20 week – higher first-phase viral decay group  
for the biphasic model 
 
Basic Statistical Measures 
Location Variability 
Mean 2.721598 Std Deviation 1.16585 
Median 2.152300 Variance 1.35920 
Mode 1.690200 Range 4.51390 






Table 3.14.6: Mean of viral load at 20 week – lower first-phase viral decay group  
for the biphasic model 
 
Basic Statistical Measures 
Location Variability 
Mean 3.818294 Std Deviation 1.10222 
Median 3.944500 Variance 1.21489 
Mode 1.690200 Range 3.98470 





Table 3.14.7: Mean of viral load at 24 week – higher first-phase viral decay group  
for the biphasic model 
 
Basic Statistical Measures 
Location Variability 
Mean 2.502958 Std Deviation 0.98654 
Median 1.690200 Variance 0.97325 
Mode 1.690200 Range 3.00260 











Table 3.14.8: Mean of viral load at 24 week – lower first-phase viral decay group  
for the biphasic model 
 
Basic Statistical Measures 
Location Variability 
Mean 3.692300 Std Deviation 1.23390 
Median 4.039300 Variance 1.52250 
Mode 1.690200 Range 3.67340 






Table 3.15.1: Wilcoxon Scores (Rank Sums) table for viral decay rates and long-term response  
for the single-model 
 
Wilcoxon Scores (Rank Sums) for Variable Pred 










0 81 3762.0 4374.0 137.673527 46.444444 






Table 3.15.2: Wilcoxon Scores (Rank Sums) test for viral decay rates and long-term response  
table for the single-phase model 
 
Wilcoxon Two-Sample Test 
Statistic (S) 2016.0000 
  
Normal Approximation  
Z 4.4417 
One-Sided Pr >  Z <.0001 
Two-Sided Pr > |Z| <.0001 
  
t Approximation  
One-Sided Pr >  Z <.0001 
Two-Sided Pr > |Z| <.0001 
  
Exact Test  
One-Sided Pr >=  S 1.863E-06 
Two-Sided Pr >= |S - Mean| 3.726E-06 














Table 3.15.3: Kruskal-Wallis test for viral decay rates and long-term response  










Table 3.15.4: Wilcoxon Scores (Rank Sums) test for viral decay rates and long-term response  
for the biphasic model 
 
Wilcoxon Scores (Rank Sums) for Variable Pred 










0 81 3729.0 4374.0 137.673527 46.037037 






Table 3.15.5: Wilcoxon Scores (Rank Sums) test for viral decay rates and long-term response  
for the biphasic model 
 
Wilcoxon Two-Sample Test 
Statistic (S) 2049.0000 
  
Normal Approximation  
Z 4.6814 
One-Sided Pr >  Z <.0001 
Two-Sided Pr > |Z| <.0001 
  
t Approximation  
One-Sided Pr >  Z <.0001 
Two-Sided Pr > |Z| <.0001 
  
Exact Test  
One-Sided Pr >=  S 4.639E-07 
Two-Sided Pr >= |S - Mean| 9.278E-07 





Table 3.15.6: Kruskal-Wallis test for viral decay rates and long-term response  












Table 3.16.1: Confusion Matrix for the single-phase model 
 
 Responder Non-responder Total 
Correct 20 51 71 
False 30 6 36 
Total 50 57 107 
 
 
Table 3.16.2: Confusion Matrix for the biphasic model 
 
 Responder Non-responder Total 
Correct 21 49 70 
False 32 5 37 





Table 3.17.1: Wilcoxon Scores (Rank Sums) table for week 1 virus load reduction and long-term response  
for the single-phase model 
 
Wilcoxon Scores (Rank Sums) for Variable LBORLGCW_S 










0 70 2864.0 3325.0 115.325626 40.914286 





Table 3.17.2: Wilcoxon Scores (Rank Sums) test for week 1 virus load reduction and long-term response  
for the single-phase model 
 
Wilcoxon Two-Sample Test 
Statistic (S) 1601.0000 
  
Normal Approximation  
Z 3.9930 
One-Sided Pr >  Z <.0001 
Two-Sided Pr > |Z| <.0001 
  
t Approximation  
One-Sided Pr >  Z <.0001 
Two-Sided Pr > |Z| 0.0001 
  
Exact Test  
One-Sided Pr >=  S 1.813E-05 
Two-Sided Pr >= |S - Mean| 3.626E-05 










Table 3.17.3: Kruskal-Wallis test for week 1 virus load reduction and long-term response  










Table 3.17.4: Wilcoxon Scores (Rank Sums) table for week 1 virus load reduction and long-term response  
for the biphasic model 
 
Wilcoxon Scores (Rank Sums) for Variable LBORLGCW_S 










0 70 2864.0 3325.0 115.325626 40.914286 





Table 3.17.5: Wilcoxon Scores (Rank Sums) test for week 1 virus load reduction and long-term response  
for the biphasic model 
 
Wilcoxon Two-Sample Test 
Statistic (S) 1601.0000 
  
Normal Approximation  
Z 3.9930 
One-Sided Pr >  Z <.0001 
Two-Sided Pr > |Z| <.0001 
  
t Approximation  
One-Sided Pr >  Z <.0001 
Two-Sided Pr > |Z| 0.0001 
  
Exact Test  
One-Sided Pr >=  S 1.813E-05 
Two-Sided Pr >= |S - Mean| 3.626E-05 





Table 3.17.6: Kruskal-Wallis test for week 1 virus load reduction and long-term response  












Table 3.18.1: Maximum Likelihood Analysis of Variance table for the single-phase model 
 
Maximum Likelihood Analysis of Variance 
Source DF Chi-Square Pr > ChiSq 
Intercept 1 20.64 <.0001 
atrtgrp 3 4.42 0.2192 





Table 3.18.2: Analysis of Maximum Likelihood Estimates for the single-phase model 
 
Analysis of Maximum Likelihood Estimates 




Square Pr > ChiSq 
Intercept  1.4183 0.3121 20.64 <.0001 
atrtgrp contro 1.6262 0.7882 4.26 0.0391 
dose 1 -0.5020 0.4300 1.36 0.2431 





Table 3.18.3: Maximum Likelihood Analysis of Variance table for the biphasic model 
 
Maximum Likelihood Analysis of Variance 
Source DF Chi-Square Pr > ChiSq 
Intercept 1 20.64 <.0001 
atrtgrp 3 4.42 0.2192 





Table 3.18.4: Analysis of Maximum Likelihood Estimates for the biphasic model 
 
Analysis of Maximum Likelihood Estimates 




Square Pr > ChiSq 
Intercept  1.4183 0.3121 20.64 <.0001 
atrtgrp contro 1.6262 0.7882 4.26 0.0391 
dose 1 -0.5020 0.4300 1.36 0.2431 
















< SAS code for the analyses > 
/* Dataset1 Importing */ 
Proc IMPORT OUT= viral 
            DataFILE= "C:\thesis\viral.xls" 
            DBMS=EXCEL REPLACE; 
     SHEET="viral$";  
     GETNAMES=YES; 
     MIXED=NO; 
     SCANTEXT=YES; 
     USEDATE=YES; 
     SCANTIME=YES; 
Run; 
 
/* Dataset2 Importing */ 
Proc IMPORT OUT= base_cov 
            DataFILE= "C:\thesis\base_cov.xls" 
            DBMS=EXCEL REPLACE; 
     SHEET="base_cov$";  
     GETNAMES=YES; 
     MIXED=NO; 
     SCANTEXT=YES; 
     USEDATE=YES; 
     SCANTIME=YES; 
Run; 
 
/* Dataset3 Importing */ 
Proc IMPORT OUT= prop 
            DataFILE= "C:\thesis\prop.xls" 
            DBMS=EXCEL REPLACE; 
     SHEET="prop$";  
     GETNAMES=YES; 
     MIXED=NO; 
     SCANTEXT=YES; 
     USEDATE=YES; 
     SCANTIME=YES; 
Run; 
 
/* Making merged dataset replicating subject observations*/ 
Data test;                                                                                                                               
Merge  base_cov(keep= MULPICD2 CD4__BLC CD4__BLQ ACT20GCD subjid)  
       prop(keep= P400_OBS P400_TLO r400_tlc subjid)  
       viral;                                                               
by subjid;                                                                                                                               
Run;                                                                                                                                     
 
/* Age grouping */ 
Data test; 
Set test; 
If (AGE < 20) then AGE1 = 1;  
If (AGE >= 30 AND AGE =< 34) then AGE1 = 2;  
If (AGE >= 35 AND AGE =< 39) then AGE1 = 3;  
If (AGE >= 40 AND AGE =< 44) then AGE1 = 4;  
If (AGE >= 45 AND AGE =< 49) then AGE1 = 5;  
If (AGE >= 50 AND AGE =< 59) then AGE1 = 6;  




/* Data manipulation for excluding missing cases of response variable  
   and dropping pre-treatment measurements */ 
Data test1; 
Set test; 
If (LBACTDY < 0) then delete;  
If (KEEPLOD < 1) then delete;  
If (LBEVFLG < 1) then delete; 








/* Data manipulation for excluding observations over 24 weeks */ 
Data Data24weeks; 
Set test1; 




/* Data excluding who had no initial viral decline (seriously) */ 
Data test2; 
Set Data24weeks; 
If (SUBJID=61) then delete;  
If (SUBJID=72) then delete;  
If (SUBJID=223) then delete;  
If (SUBJID=512) then delete;  
If (SUBJID=1249) then delete;  
If (SUBJID=1300) then delete;  
If (SUBJID=1530) then delete;  
If (SUBJID=1665) then delete;  




/* Data manipulation including Data by 16 days(2 weeks) */ 
Data Data16days; 
Set test2; 





/* A single-phase nonlinear decay Model using nlmixed 
   to drive viral decay rates for 16 days (2 weeks)*/ 
/* Getting the initial values without fitting random effects using nlin */ 
Proc nlin Data=data16days; 
Parms P1=1 d1=1; 
Model LBORRLG = log10(exp(p1)*exp(-d1*LBACTDY)); 
Run; 
 
/* Fitting nlmixed with one random effect to get the initial parameter values */ 
Proc nlmixed Data=data16days; 
Parms P1=10.488 d1=0.169 error=1.089 varcomp11=1;  
u1=d1+b1; 
expected = log10(exp(P1)*exp(-u1*LBACTDY)); 
Model LBORRLG ~ normal(expected, error**2);  
      Random b1 ~normal([0], [varcomp11]) subject=SUBJID; 
      Predict u1 out= ratepredic1_1_0; 
Run; 
 
/* Fitting nlmixed with full random effect of a single-phase model using the initial 
values */ 
 Proc nlmixed Data=Data16days; 
 Parms P1=10.476  
       d1=0.167 
       error=0.541 
       varcomp11=0.05  
       varcomp12=0.01 to 1 by 0.01 
       varcomp22=0.01 to 1 by 0.01;  
u1=d1+b1; 
u2=P1+b2; 
expected = log10(exp(u2)*exp(-u1*LBACTDY)); 
Model LBORRLG ~ normal(expected, error**2);  
      Random b1 b2 ~normal([0,0], [varcomp11,varcomp12,varcomp22]) subject=SUBJID; 
      Predict u1 out= ratepredic1_1; 
      Predict u2 out= ratepredic1_2; 
Run;  
ods rtf close; 
 
 
/* A bi-phasic nonlinear decay Model using nlmixed 
   to drive viral decay rates by 16 days (2 weeks) */ 
/* Getting the initial values without fitting random effects using nlin */ 
Proc nlin Data=data16days; 
Parms P1=10.476 P2=1 d1=0.169 d2=1; 






/* Data manipulation to get initial values for nlmixed model */ 
data Data16days1; 
set Data16days; 
where atrtgrp='dose 1' or atrtgrp='dose 2' or atrtgrp='dose 3'; 
run; 
/* Fitting nlmixed with two random effects of biphasic model using the initial values from 
nlin */ 
ods rtf; 
Proc nlmixed Data=Data16days1; 




expected = log10(exp(u3)*exp(-u1*LBACTDY)+exp(P2)*exp(-d2*LBACTDY)); 
Model LBORRLG ~ normal(expected, error**2);  
      Random b1 b3 ~normal([0,0],  
      [varcomp11,varcomp13,varcomp33]) subject=SUBJID; 
      Predict u1 out= ratepredic2_1_0; 
   Predict u3 out= ratepredic2_3_0; 
Run;  
ods rtf close; 
/* Fitting nlmixed with three random effects but without covariance of biphasic model  
   using the estimated values from the previous nlmixed model */ 
ods rtf; 
Proc nlmixed Data=data16days;   
Parms P1=10.1 P2=9.62 d1=0.169 d2=0.885 error=0.2868 
      varcomp11=0.019  
      varcomp22=0.01 to 1 by 0.01 




expected = log10(exp(u3)*exp(-u1*LBACTDY)+exp(P2)*exp(-u2*LBACTDY)); 
Model LBORRLG ~ normal(expected, error**2);  
      Random b1 b2 b3 ~normal([0,0,0],  
      [varcomp11,0 ,varcomp22 ,0 ,0 ,varcomp33]) subject=SUBJID; 
      Predict u1 out= ratepredic2_1_1_0; 
   Predict u2 out= ratepredic2_2_1_0; 
      Predict u3 out= ratepredic2_3_3_0; 
Run;  
ods rtf close; 
/* Fitting nlmixed with three random effect and covariances of biphasic model  
   using the estimated values from the previous nlmixed model */ 
ods rtf; 
Proc nlmixed Data=data16days;   
Parms P1=10.1 P2=9.62 d1=0.169 d2=0.885 error=0.2868 
      varcomp11=0.019 
      varcomp22=0.01 to 1 by 0.01 
      varcomp33=4.77 
      varcomp13=0.000001 
      varcomp23=0.000001 




expected = log10(exp(u3)*exp(-u1*LBACTDY)+exp(P2)*exp(-u2*LBACTDY)); 
Model LBORRLG ~ normal(expected, error**2);  
      Random b1 b2 b3 ~normal([0,0,0],  
      [varcomp11,varcomp12,varcomp22,varcomp13,varcomp23,varcomp33]) subject=SUBJID; 
      Predict u1 out= ratepredic2_1_1; 
   Predict u2 out= ratepredic2_2_2; 
      Predict u3 out= ratepredic2_3_3; 
Run;  
ods rtf close; 
 
 
/* Changing into a numeric value */ 
Data RatePredic1_11; 
Set RatePredic1_1; 
If SEX='M' then SEX1=1;  
If SEX='F' then SEX1=2;  
If RACE='White - White/Caucasian/European Heritage' then RACE1=1; 
If RACE='White - Arabic/North African Heritage' then RACE1=1; 
If RACE='African American/African Heritage' then RACE1=2; 
If atrtgrp='dose 1' then atrtgrp1=1; 
If atrtgrp='dose 2' then atrtgrp1=2; 




If atrtgrp='contro' then atrtgrp1=4; 
Run;   
 
/* Changing into a numeric value */ 
Data RatePredic2_11; 
Set RatePredic2_1_1; 
If SEX='M' then SEX1=1;  
If SEX='F' then SEX1=2;  
If RACE='White - White/Caucasian/European Heritage' then RACE1=1; 
If RACE='White - Arabic/North African Heritage' then RACE1=1; 
If RACE='African American/African Heritage' then RACE1=2; 
If atrtgrp='dose 1' then atrtgrp1=1; 
If atrtgrp='dose 2' then atrtgrp1=2; 
If atrtgrp='dose 3' then atrtgrp1=3; 
If atrtgrp='contro' then atrtgrp1=4; 
Run;   
 
 
/* Changing into a numeric value */ 
Data RatePredic2_22; 
Set RatePredic2_2_2; 
If SEX='M' then SEX1=1;  
If SEX='F' then SEX1=2;  
If RACE='White - White/Caucasian/European Heritage' then RACE1=1; 
If RACE='White - Arabic/North African Heritage' then RACE1=1; 
If RACE='African American/African Heritage' then RACE1=2; 
If atrtgrp='dose 1' then atrtgrp1=1; 
If atrtgrp='dose 2' then atrtgrp1=2; 
If atrtgrp='dose 3' then atrtgrp1=3; 
If atrtgrp='contro' then atrtgrp1=4; 
Run;   
 
 
/* Dataset4 Importing contains results of predicted d1,baseline RNA  
   for each subject from the single-phase model */ 
Proc IMPORT OUT= pred11 
            DataFILE= "C:\thesis2\pred11.xls" 
            DBMS=EXCEL REPLACE; 
     SHEET="Sheet1$";  
     GETNAMES=YES; 
     MIXED=NO; 
     SCANTEXT=YES; 
     USEDATE=YES; 




/* Dataset5 Importing contains results of predicted d1,baseline RNA  
   for each subject from the biphasic model */ 
Proc IMPORT OUT= pred2_11 
            DataFILE= "C:\thesis2\pred2_11.xls" 
            DBMS=EXCEL REPLACE; 
     SHEET="Sheet1$";  
     GETNAMES=YES; 
     MIXED=NO; 
     SCANTEXT=YES; 
     USEDATE=YES; 
     SCANTIME=YES; 
Run; 
 
/* Dataset6 Importing contains results of predicted d2,baseline RNA  
   for each subject from the biphasic model */ 
Proc IMPORT OUT= pred2_22 
            DataFILE= "C:\thesis2\pred2_22.xls" 
            DBMS=EXCEL REPLACE; 
     SHEET="Sheet1$";  
     GETNAMES=YES; 
     MIXED=NO; 
     SCANTEXT=YES; 
     USEDATE=YES; 










/* Spearman's rank tests for initial viral decay rates(d1) and log10 baseline RNA  */ 
ods rtf; 
Proc corr data=Pred11 spearman plots; 
      var Pred LBORRLG; 
   run; 
Proc corr data=Pred2_11 spearman plots; 
      var Pred LBORRLG; 
   run; 
ods rtf close; 
 
 
/* Plot of initial viral decay rates(d1) and log10 baseline RNA  
   by actual treatment groups for the single-phase model */ 
ods rtf; 
TITLE height=10pt "r=-0.292, p<.0001"; 
Proc gplot Data=Pred11;  
      symbol v=dot h=0.5; 
      LABEL Pred='RNA decay rate,d1'; 
      LABEL LBORRLG='Log10 baseline RNA, copies/mL';  
      plot Pred * LBORRLG=ATRTGRP;  
   Run;  
/* Plot of initial viral decay rates(d1) and log10 baseline RNA  
   by actual treatment groups for the biphasic model */ 
TITLE height=10pt "r=-0.414, p<.0001"; 
Proc gplot Data=Pred2_11;  
      symbol v=dot h=0.5; 
      LABEL Pred='RNA decay rate,d1'; 
      LABEL LBORRLG='Log10 baseline RNA, copies/mL';  
      plot Pred * LBORRLG=ATRTGRP;  
   Run;  
ods rtf close; 
 
 
/* Dataset7 Importing contains results of predicted d1, week 1 log10 RNA change from 
baseline for each subject from the single-phase model */ 
Proc IMPORT OUT= pred11_change 
            DataFILE= "C:\thesis2\pred11_change.xls" 
            DBMS=EXCEL REPLACE; 
     SHEET="sheet1$";  
     GETNAMES=YES; 
     MIXED=NO; 
     SCANTEXT=YES; 
     USEDATE=YES; 
     SCANTIME=YES; 
Run; 
 
/* Dataset8 Importing contains results of predicted d1, week 1 log10 RNA change from 
baseline for each subject from the biphasic model */ 
Proc IMPORT OUT= pred2_11_change 
            DataFILE= "C:\thesis2\pred2_11_change.xls" 
            DBMS=EXCEL REPLACE; 
     SHEET="sheet1$";  
     GETNAMES=YES; 
     MIXED=NO; 
     SCANTEXT=YES; 
     USEDATE=YES; 




/* Spearman's rank tests for initial viral decay rates(d1) and week 1 log10 RNA change 
from baseline  */ 
ods rtf; 
Proc corr data=Pred11_change spearman plots; 
      var Pred LBORLGCW_S; 
   run; 
Proc corr data=Pred2_11_change spearman plots; 
      var Pred LBORLGCW_S; 
   run; 
ods rtf close; 
 
 
/* Dataset9 Importing contains results of week 20 log10 RNA change from baseline */ 
Proc IMPORT OUT= d20week 
            DataFILE= "C:\thesis2\d20week.xls" 
            DBMS=EXCEL REPLACE; 




     GETNAMES=YES; 
     MIXED=NO; 
     SCANTEXT=YES; 
     USEDATE=YES; 
     SCANTIME=YES; 
Run; 
 
/* Making merged dataset replicating subject observations */ 
Data Pred11_change_1;                                                                                                                               
Merge  d20week(keep= LBORLGCW1_S subjid)  
       Pred11_change;                                                               
by subjid;                                                                                                                               
Run;  
Data Pred2_11_change_1;                                                                                                                               
Merge  d20week(keep= LBORLGCW1_S subjid)  
       Pred2_11_change;                                                               
by subjid;                                                                                                                               
Run;  
 
/* Spearman's rank tests for week 1 log10 RNA change from baseline and week 20 log10 RNA 
change from baseline */ 
ods rtf; 
Proc corr data=Pred11_change_1 spearman plots; 
      var LBORLGCW_S LBORLGCW1_S; 
   run; 
Proc corr data=Pred2_11_change_1 spearman plots; 
      var LBORLGCW_S LBORLGCW1_S; 
   run; 
ods rtf close; 
 
 
/* Spearman's rank tests for initial viral decay rates and week 20 log10 RNA change from 
baseline */ 
ods rtf; 
Proc corr data=Pred11_change_1 spearman plots; 
      var pred LBORLGCW1_S; 
   run; 
Proc corr data=Pred2_11_change_1 spearman plots; 
      var Pred LBORLGCW1_S; 
   run; 
ods rtf close; 
 
/* Dataset10 Importing contains results of week 24 log10 RNA change from baseline */ 
Proc IMPORT OUT= d24week 
            DataFILE= "C:\thesis2\d24week.xls" 
            DBMS=EXCEL REPLACE; 
     SHEET="sheet1$";  
     GETNAMES=YES; 
     MIXED=NO; 
     SCANTEXT=YES; 
     USEDATE=YES; 
     SCANTIME=YES; 
Run; 
 
/* Making merged dataset replicating subject observations */ 
Data Pred11_change_11;                                                                                                                               
Merge  d24week(keep= LBORLGCW1_S subjid)  
       Pred11_change;                                                               
by subjid;                                                                                                                               
Run;  
Data Pred2_11_change_11;                                                                                                                               
Merge  d24week(keep= LBORLGCW1_S subjid)  
       Pred2_11_change;                                                               
by subjid;                                                                                                                               
Run;  
 
/* Spearman's rank tests for week 1 log10 RNA change from baseline and week 24 log10 RNA 
change from baseline */ 
ods rtf; 
Proc corr data=Pred11_change_11 spearman plots; 
      var LBORLGCW_S LBORLGCW1_S; 
   run; 
Proc corr data=Pred2_11_change_11 spearman plots; 
      var LBORLGCW_S LBORLGCW1_S; 
   run; 





/* Spearman's rank tests for initial viral decay rates and week 24 log10 RNA change from 
baseline */ 
ods rtf; 
Proc corr data=Pred11_change_11 spearman plots; 
      var pred LBORLGCW1_S; 
   run; 
Proc corr data=Pred2_11_change_11 spearman plots; 
      var Pred LBORLGCW1_S; 
   run; 




/* Plot of initial viral decay rates(d1) and week 1 log10 RNA change from baseline  
   by actual treatment groups for the single-phase model */ 
ods rtf; 
TITLE height=10pt "r=0.867, p<.0001"; 
Proc gplot Data=Pred11_change;  
      symbol v=dot h=0.5; 
      LABEL Pred='RNA decay rate,d1'; 
      LABEL LBORLGCW_S='Week 1 Log10 RNA change from baseline, copies/mL';  
      plot Pred * LBORLGCW_S=ATRTGRP;  
   Run;  
/* Plot of initial viral decay rates(d1) and week 1 log10 RNA change from baseline  
   by actual treatment groups for the biphasic model */ 
TITLE height=10pt "r=0.852, p<.0001"; 
Proc gplot Data=Pred2_11_change;  
      symbol v=dot h=0.5; 
      LABEL Pred='RNA decay rate,d1'; 
      LABEL LBORLGCW_S='Week 1 Log10 RNA change from baseline, copies/mL';  
      plot Pred * LBORLGCW_S=ATRTGRP;  
   Run;  




/* Spearman's rank tests for the initial viral decay rates(d1) and CD4__BLC */ 
ods rtf; 
Proc corr data=Pred11 spearman plots; 
      var Pred CD4__BLC; 
   run; 
Proc corr data=Pred2_11 spearman plots; 
      var Pred CD4__BLC; 
   run; 




/* ANOVA for age effect on d1 decay rates */ 








/* ANOVA for gender effect on d1 decay rates */ 




Proc anova data=pred2_11; 
class sex; 
model pred=sex; 
/* ANOVA for ethnicity effect on d1 decay rates */ 








/* ANOVA for actual treatment group effect on d1 decay rates */ 















/* A univariate regression analysis for actual treatment, age, gender, and ethnicity 
groups */ 
Proc reg data=pred11; 
model pred=atrtgrp1; run; 
Proc reg data=pred2_11; 
model pred=atrtgrp1; run; 
Proc reg data=pred11; 
model pred=AGE; run; 
Proc reg data=pred2_11; 
model pred=AGE; run; 
Proc reg data=pred11; 
model pred=SEX1; run; 
Proc reg data=pred2_11; 
model pred=SEX1; run; 
Proc reg data=pred11; 
model pred=RACE1; run; 
Proc reg data=pred2_11; 
model pred=RACE1; run; 
 
 
/* Npar1way for examining relationship between the initial decay rates and actual 
treatment group */ 
ods rtf;  
Proc npar1way wilcoxon data=Pred11; 
      class atrtgrp1 ; 
      var Pred; /* response variable */ 
   run; 
Proc npar1way wilcoxon data=Pred2_11; 
      class  atrtgrp1; 
      var Pred; /* response variable */ 
   run; 
ods rtf close;  
 
/* Mean of each actual treatment group */ 
Proc sort data=pred11; 
by atrtgrp1; run; 
ods rtf;  
Proc univariate data=pred11;  
var pred; 
by atrtgrp1; run; 
ods rtf close;  
 
Proc sort data=pred2_11; 
by atrtgrp1; run; 
ods rtf;  
Proc univariate data=pred2_11;  
var pred; 
by atrtgrp1; run; 
ods rtf close;  
 
 
/* GLM for examining relationship between the initial decay rates and actual treatment 
group */ 
ods rtf;  
Proc glm Data=Ratepredic1_11;  
      class SUBJID ATRTGRP;  
      Model Pred= ATRTGRP;  
      manova h=_all_ / /* printe printh */;  
      means ATRTGRP/CLDIfF bon tukey; 
   run;  
Proc glm Data=Ratepredic2_11;  
      class SUBJID ATRTGRP;  
      Model Pred= ATRTGRP;  
      manova h=_all_ / /* printe printh */;  
      means ATRTGRP/CLDIfF bon tukey; 
   Run; 




/* GLM for identifying baseline characteristics which are correlated with decay rates */ 
ods rtf;  
Proc glm Data=Pred11;  
      class SUBJID AGE SEX RACE ATRTGRP ACT20GCD MULPICD2 ;  
      Model Pred= AGE SEX RACE CD4__BLC LBORRLG ATRTGRP MULPICD2 ACT20GCD ;  
      manova h=_all_ / /* printe printh */;  
      means AGE SEX RACE ATRTGRP MULPICD2 ACT20GCD/CLDIfF tukey; 
   Run; 
Proc glm Data=Pred2_11;  
      class SUBJID AGE SEX RACE ATRTGRP ACT20GCD MULPICD2 ;  
      Model Pred= AGE SEX RACE CD4__BLC LBORRLG ATRTGRP MULPICD2 ACT20GCD ;  
      manova h=_all_ / /* printe printh */;  
      means AGE SEX RACE ATRTGRP MULPICD2 ACT20GCD/CLDIfF tukey; 
   Run; 
ods rtf close;  
 
 
/* Npar1way for examining whether the initial decay rates Predict long term response */ 
ods rtf;  
Proc npar1way wilcoxon data=Pred11; 
      class  P400_TLO; 
      var Pred; /* response variable */ 
      exact; 
   run; 
Proc npar1way wilcoxon data=Pred2_11; 
      class  P400_TLO; 
      var Pred; /* response variable */ 
      exact; 
   run; 
ods rtf close;  
 
Proc insight data=Pred11; run; 
Proc insight data=Pred2_11; run; 
Proc insight data=Pred2_22; run; 
 
 
/* Making merged dataset with the variable of week 20 viral load */ 
data pred11_a;                                                                                                                               
Merge  d20week(keep= LBORRLG1 subjid)  
       pred11;                                                               
by subjid;                                                                                                                               
Run;  
/* Subjects who have higher decay rates for the single-phase model */ 
Data Pred11_aa; 
set Pred11_a; 
if pred < 0.168 then delete; run; 
/* Subjects who have lower decay rates for the single-phase model */ 
Data Pred11_aaa; 
set Pred11_a; 
if pred >= 0.168 then delete; run; 
 
Proc insight data=Pred11_aa; run; 
Proc insight data=Pred11_aaa; run; 
 
/* Making merged dataset with the variable of week 24 viral load */ 
data pred11_b;                                                                                                                               
Merge  d24week(keep= LBORRLG1 subjid)  
       pred11;                                                               
by subjid;                                                                                                                               
Run;  
/* Subjects who have higher decay rates for the single-phase model */ 
Data Pred11_bb; 
set Pred11_b; 
if pred < 0.168 then delete; run; 
/* Subjects who have lower decay rates for the single-phase model */ 
Data Pred11_bbb; 
set Pred11_b; 
if pred >= 0.168 then delete; run; 
 
Proc insight data=Pred11_bb; run; 










/* Making merged dataset with the variable of week 20 viral load */ 
data pred2_11_a;                                                                                                                               
Merge  d20week(keep= LBORRLG1 subjid)  
       pred2_11;                                                               
by subjid;                                                                                                                               
Run; 
/* Subjects who have higher decay rates for the biphasic model */ 
Data Pred2_11_aa; 
set Pred2_11_a; 
if pred < 0.097 then delete; run; 
/* Subjects who have lower decay rates for the biphasic model */ 
Data Pred2_11_aaa; 
set Pred2_11_a; 
if pred >= 0.097 then delete; run; 
 
Proc insight data=Pred2_11_aa; run; 
Proc insight data=Pred2_11_aaa; run; 
 
/* Making merged dataset with the variable of week 24 viral load */ 
data pred2_11_b;                                                                                                                               
Merge  d24week(keep= LBORRLG1 subjid)  
       pred2_11;                                                               
by subjid;                                                                                                                               
Run;  
/* Subjects who have higher decay rates for the biphasic model */ 
Data Pred2_11_bb; 
set Pred2_11_b; 
if pred < 0.097 then delete; run; 
/* Subjects who have lower decay rates for the biphasic model */ 
Data Pred2_11_bbb; 
set Pred2_11_b; 
if pred >= 0.097 then delete; run; 
 
Proc insight data=Pred2_11_bb; run; 
Proc insight data=Pred2_11_bbb; run; 
 
 
/* Mean of week 20/24 viral load */  
ods rtf;  
Proc univariate data=Pred11_aa; 
var LBORRLG1; run; 
Proc univariate data=Pred11_aaa; 
var LBORRLG1; run; 
Proc univariate data=Pred11_bb; 
var LBORRLG1; run; 
Proc univariate data=Pred11_bbb; 
var LBORRLG1; run; 
Proc univariate data=Pred2_11_aa; 
var LBORRLG1; run; 
Proc univariate data=Pred2_11_aaa; 
var LBORRLG1; run; 
Proc univariate data=Pred2_11_bb; 
var LBORRLG1; run; 
Proc univariate data=Pred2_11_bbb; 
var LBORRLG1; run; 
ods rtf close;  
 
/* Dataset11 Importing contains results of week 24 log10 RNA change from baseline */ 
Proc IMPORT OUT= Pred11_test222 
            DataFILE= "C:\thesis2\Pred11_test222.xls" 
            DBMS=EXCEL REPLACE; 
     SHEET="Pred11_test222$";  
     GETNAMES=YES; 
     MIXED=NO; 
     SCANTEXT=YES; 
     USEDATE=YES; 
     SCANTIME=YES; 
Run; 
/* Making merged dataset replicating subject observations */ 
data pred11_test2222;                                                                                                                               
Merge  pred11_test222(keep= LBORRLG2 subjid)  
       pred11_test333;                                                               








/* Confusion matrix for the initial decay rates and long-term response variable  












if predicted=1 AND P400_TLO=1 then correctresp=1; 
if predicted=0 AND P400_TLO=0 then correctnonresp=1; 
if predicted=1 AND P400_TLO=0 then falseresp=1; 
if predicted=0 AND P400_TLO=1 then falsenonresp=1; 
run; 
Proc insight data=compare1; 
run; 
Proc freq data=compare1; 




/* Confusion matrix for the initial decay rates and long-term response variable  












if predicted=1 AND P400_TLO=1 then correctresp=1; 
if predicted=0 AND P400_TLO=0 then correctnonresp=1; 
if predicted=1 AND P400_TLO=0 then falseresp=1; 
if predicted=0 AND P400_TLO=1 then falsenonresp=1; 
run; 
Proc insight data=compare2; 
run; 
Proc freq data=compare2; 
tables correctresp correctnonresp falseresp falsenonresp/out=FreqCnt; 
run; 
 
ods rtf;  
 
 
/* Npar1way for examining relationship between week 1 virus load reduction and long-term 
response  */ 
Proc npar1way wilcoxon data=Pred11_change; 
      class  P400_TLO; 
      var LBORLGCW_S; /* response variable */ 
      exact; 
   run; 
Proc npar1way wilcoxon data=Pred2_11_change; 
      class  P400_TLO; 
      var LBORLGCW_S; /* response variable */ 
      exact; 
   run; 
ods rtf close;  
 
 
/* The univariate logistic regression analyses for the long-term response  
   and actual treatment group */  
ods rtf;  
Proc catmod data=pred11; 
model P400_TLO=atrtgrp; 
run; 
Proc catmod data=pred2_11; 
model P400_TLO=atrtgrp; 
run; 






Proc insight data=Ratepredic1_11; run; 
Proc insight data=pred11; run; 
Proc insight data=pred2_11; run; 
Proc insight data=pred2_22; run; 
Proc insight data=Pred11_change; run; 





/* Graph Section */ 
ods rtf;  
/* Gplots 1-1 of viral load result for 7 randomly selected individual */ 
DATA data24weeks_1_1; /* New SAS data file name */ 
SET data24weeks; 
IF (SUBJID < 251) THEN DELETE;  
IF (SUBJID > 355) THEN DELETE;  
run; 
/* TITLE "Plot of Windowed original numeric result" */  
/* Proc gplot data=data24weeks_1;  
      symbol i=line v=dot h=0.5;  
      LABEL LBORRSNW='Windowed original N/R'; 
      LABEL LBACTDY='Time(days) since start of treatment';  
      plot LBORRSNW * LBACTDY=SUBJID/NOLEGEND href=16 href=30 lhref=2;  
   run; */ 
/* TITLE "Plot of Windowed log10 original numeric result" */ 
Proc gplot data=data24weeks_1_1;  
      symbol i=line v=dot h=0.5;  
      LABEL LBORRLGW='log10 RNA'; 
      LABEL LBACTDY='Time(days) since start of treatment';  
      plot LBORRLGW * LBACTDY=SUBJID/NOLEGEND href=16 href=30 lhref=2;  
   run;  
/* TITLE "Plot of Windowed change from baseline log 10" */ 
/* Proc gplot data= data24weeks_1;  
      symbol i=line v=dot h=0.5;  
      LABEL LBORLGCW='W/C from baseline log 10'; 
      LABEL LBACTDY='Time(days) since start of treatment';  
      plot LBORLGCW * LBACTDY=SUBJID/NOLEGEND href=16 href=30 lhref=2;  
   run; */ 
 
/* Gplots 1-2 of viral load result for 7 randomly selected individual */ 
DATA data24weeks_1_2; /* New SAS data file name */ 
SET data24weeks; 
IF (SUBJID < 565) THEN DELETE;  
IF (SUBJID > 574) THEN DELETE;  
run; 
/* TITLE "Plot of Windowed log10 original numeric result" */ 
Proc gplot data=data24weeks_1_2;  
      symbol i=line v=dot h=0.5;  
      LABEL LBORRLGW='log10 RNA'; 
      LABEL LBACTDY='Time(days) since start of treatment';  
      plot LBORRLGW * LBACTDY=SUBJID/NOLEGEND href=16 href=30 lhref=2;  
   run;  
 
/* Gplots 1-3 of viral load result for 7 randomly selected individual */ 
DATA data24weeks_1_3; /* New SAS data file name */ 
SET data24weeks; 
IF (SUBJID < 831) THEN DELETE;  
IF (SUBJID > 1250) THEN DELETE;  
run; 
/* TITLE "Plot of Windowed log10 original numeric result" */ 
Proc gplot data=data24weeks_1_3;  
      symbol i=line v=dot h=0.5;  
      LABEL LBORRLGW='log10 RNA'; 
      LABEL LBACTDY='Time(days) since start of treatment';  
      plot LBORRLGW * LBACTDY=SUBJID/NOLEGEND href=16 href=30 lhref=2;  
   run;  
 
 
/* Gplots 1-4 of viral load result for 7 randomly selected individual */ 
DATA data24weeks_1_4; /* New SAS data file name */ 
SET data24weeks; 
IF (SUBJID < 1570) THEN DELETE;  





/* TITLE "Plot of Windowed log10 original numeric result" */ 
Proc gplot data=data24weeks_1_4;  
      symbol i=line v=dot h=0.5;  
      LABEL LBORRLGW='log10 RNA'; 
      LABEL LBACTDY='Time(days) since start of treatment';  
      plot LBORRLGW * LBACTDY=SUBJID/NOLEGEND href=16 href=30 lhref=2;  
   run;  
 
/* Gplots 1-5 of viral load result for 7 randomly selected individual */ 
DATA data24weeks_1_5; /* New SAS data file name */ 
SET data24weeks; 
IF (SUBJID < 1701) THEN DELETE;  
IF (SUBJID > 1832) THEN DELETE;  
run; 
/* TITLE "Plot of Windowed log10 original numeric result" */ 
Proc gplot data=data24weeks_1_5;  
      symbol i=line v=dot h=0.5;  
      LABEL LBORRLGW='log10 RNA'; 
      LABEL LBACTDY='Time(days) since start of treatment';  
      plot LBORRLGW * LBACTDY=SUBJID/NOLEGEND href=16 href=30 lhref=2;  
   run;  
 
/* Gplots 1-6 of viral load result for 7 randomly selected individual */ 
DATA data24weeks_1_6; /* New SAS data file name */ 
SET data24weeks; 
IF (SUBJID < 1890) THEN DELETE;  
IF (SUBJID > 2020) THEN DELETE;  
run; 
/* TITLE "Plot of Windowed log10 original numeric result" */ 
Proc gplot data=data24weeks_1_6;  
      symbol i=line v=dot h=0.5;  
      LABEL LBORRLGW='log10 RNA'; 
      LABEL LBACTDY='Time(days) since start of treatment';  
      plot LBORRLGW * LBACTDY=SUBJID/NOLEGEND href=16 href=30 lhref=2;  
   run;  
ods rtf close;  
 
 
/* Gplots 2 by responder/non responders */ 
ods rtf;  
DATA data24weeks_1_7; 
SET data24weeks; 
WHERE r400_tlc = '6'; 
run; 
TITLE height=12pt font=regular "(A) Responder at visit and censored thereafter";  
Proc gplot data=data24weeks_1_7;  
      symbol i=line v=dot h=0.5;  
      LABEL LBORRLGW='log10 RNA'; 
      LABEL LBACTDY='Time(days) since start of treatment';  
      plot LBORRLGW * LBACTDY=SUBJID/NOLEGEND href=16 href=30 lhref=2;  
   run;  
ods rtf close; 
DATA data24weeks_1_8; 
SET data24weeks; 
WHERE r400_tlc = '2.27'; 
run; 
TITLE height=12pt font=regular "(B) Protocol mandated switch from 150mg BCV/r";  
Proc gplot data=data24weeks_1_8;  
      symbol i=line v=dot h=0.5;  
      LABEL LBORRLGW='log10 RNA'; 
      LABEL LBACTDY='Time(days) since start of treatment';  
      plot LBORRLGW * LBACTDY=SUBJID/NOLEGEND href=16 href=30 lhref=2;  




WHERE r400_tlc = '3'; 
run; 
TITLE height=12pt font=regular "(C) Never achieved VL suppression by Week 24"; 
Proc gplot data=data24weeks_1_9;  
      symbol i=line v=dot h=0.5;  
      LABEL LBORRLGW='log10 RNA'; 
      LABEL LBACTDY='Time(days) since start of treatment';  
      plot LBORRLGW * LBACTDY=SUBJID/NOLEGEND href=16 href=30 lhref=2;  








WHERE r400_tlc = '5'; 
run; 
TITLE height=12pt font=regular "(D) Plasma HIV-1 RNA rebound"; 
Proc gplot data=data24weeks_1_10;  
      symbol i=line v=dot h=0.5;  
      LABEL LBORRLGW='log10 RNA'; 
      LABEL LBACTDY='Time(days) since start of treatment';  
      plot LBORRLGW * LBACTDY=SUBJID/NOLEGEND href=16 href=30 lhref=2;  




WHERE r400_tlc = '2.10'; 
run; 
TITLE height=12pt font=regular "(E) Insufficient viral load response"; 
Proc gplot data=data24weeks_1_11;  
      symbol i=line v=dot h=0.5;  
      LABEL LBORRLGW='log10 RNA'; 
      LABEL LBACTDY='Time(days) since start of treatment';  
      plot LBORRLGW * LBACTDY=SUBJID/NOLEGEND href=16 href=30 lhref=2;  
   run;  
ods rtf close; 
 
 
/* Gplots 3 for treatment group*/ 
ods rtf;  
DATA data24weeks_1_12; 
SET data24weeks; 
WHERE ATRTGRP = 'dose 1'; 
run; 
TITLE height=12pt font=regular "(A) dose 1 group"; 
Proc gplot data=data24weeks_1_12;  
      symbol i=line v=dot h=0.5;  
      LABEL LBORRLGW='log10 RNA'; 
      LABEL LBACTDY='Time(days) since start of treatment';  
      plot LBORRLGW * LBACTDY=SUBJID/NOLEGEND href=16 href=30 lhref=2;  




WHERE ATRTGRP = 'dose 2'; 
run; 
TITLE height=12pt font=regular "(B) dose 2 group"; 
Proc gplot data=data24weeks_1_13;  
      symbol i=line v=dot h=0.5;  
      LABEL LBORRLGW='log10 RNA'; 
      LABEL LBACTDY='Time(days) since start of treatment';  
      plot LBORRLGW * LBACTDY=SUBJID/NOLEGEND href=16 href=30 lhref=2;  




WHERE ATRTGRP = 'dose 3'; 
run; 
TITLE height=12pt font=regular "(C) dose 3 group"; 
Proc gplot data=data24weeks_1_14;  
      symbol i=line v=dot h=0.5;  
      LABEL LBORRLGW='log10 RNA'; 
      LABEL LBACTDY='Time(days) since start of treatment';  
      plot LBORRLGW * LBACTDY=SUBJID/NOLEGEND href=16 href=30 lhref=2;  




WHERE ATRTGRP = 'contro'; 
run; 
TITLE height=12pt font=regular "(D) control group"; 
Proc gplot data=data24weeks_1_15;  
      symbol i=line v=dot h=0.5;  
      LABEL LBORRLGW='log10 RNA'; 
      LABEL LBACTDY='Time(days) since start of treatment';  
      plot LBORRLGW * LBACTDY=SUBJID/NOLEGEND href=16 href=30 lhref=2;  
   run;  
ods rtf close;  
 
